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一 — —Damage to the central nervous system (CNS) elicits complex responses, which 
subsequently leads to glial scar formation, and this process has been shown to impede 
neuron regeneration. Among the responses，it was observed that the level of tumor 
necrosis factor-a (TNF-a) was greatly elevated at the site of injury, and that inhibitors 
of TNF-a gene expression significantly improved the outcome of injury suggesting 
that TNF-a mediates pathological events following brain injury. Accumulated 
evidence showed that astrocytes, the most abundant cell type in the CNS, were 
activated by cytokines, including TNF-a, then underwent proliferation and 
astrogliosis, both processes are closely related to glial scar formation. Recently, it was 
aiso found that P-adrenergic blockade reduced astrogliosis suggesting that (3-
adrenergic mechanism was closely related to glial scar formation. However, the 
relationship between the TNF-a and P-adrenergic-mediated events remains unclear. 
The aims of this project are (i) to investigate whether there is a relationship between 
TNF-a receptors (TNF-R) and P-AR expression, and (ii) the messenger mediating 
these two processes. 
I Results of the present study indicated that TNF-a induced the expression of 




these receptors has been shown to mediate C6 cell proliferation. The induction of p-
ARs was stimulated by phorbol 12-myristate 13-acetate (PMA), a protein kinase C 
. . - - — — - - • 
… 一 (PKC) activator, while Ro-31-8220 (Ro31), a potent PKC inhibitor, suppressed TNF-
a-induced stimulation. In addition, we observed that TNF-a, PMA and isoproterenol 
(an p-adrenergic agonist) selectively induced the expression of TNF-R2. As both 
TNF-a and isoproterenol have previously been shown to stimulate proliferation, these 
data indicated that TOT-a-induced proliferation in C6 glioma cells via the induction 
of TNF-R2 and p-AR genes, and this induction was mediated through PKC. Moreover， 
we found that P-agonists stimulated, but P-antagonists suppressed TKF-a and TNF-
a-induced TNF-R2 expression. This demonstrated that there was an interaction 
between TNP-a and P-adrenergic mechanisms in C6 cells. 
Our results showed that TNF-a, PMA and isoproterenol induced the 
transcription factor, nuclear factor-icB (NF-KB) and its target gene, manganese 
superoxide dismutase (MnSOD) expression, in C6 cells. On the other hand, 
propranolol attenuated the TNF-a-induced N F - K B and MnSOD expression in C6 cells. 
These indicated that N F - K B and MnSOD expression induced by TNF-a was mediated 
via PKC and P-adrenergic systems in C6 cells. 
Taken together, this study suggests that regulation of P K C , N F - K B and MnSOD 
should be beneficial therapeutic means, in addition to suppression of TNP-a and (3-


























myristate-13-acetate (PMA)能刺激（3-AR 的表達，而 PKC 的抑制劑 Ro-31-
8220(Ro31)可壓止TNF-a所弓丨發的反應。除此之外’我們發現TNF-a, PMA和 
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Chapter 1 TTitrndnction 
1 INTRODUCTION 
Tumor necrosis factor-a (TNF-a), a cytokine, is a pleiotropic polypeptide, 
which plays a significant role in immune and inflammatory activities in many organs, 
including the brain. For example, TNF-a has been found to be increased in the brain after 
mechanical trauma and has been suggested to serve as an important mediator of 
inflammation and microvascular injury associated with trauma (Kamei et al, 2000). 
Also, an increase in TNF-a mRNA expression has been reported following traumatic 
brain injury (Fan et al., 1996). These suggest that TNF-a plays important roles in brain 
injury. 
Apart from the increase in TNF-a, it has been shown that p-adrenergic receptors 
(P-ARs) was activated following brain injury (Hodges-Salova et al., 1996), and they play 
important roles mediating injury-induced astrogliosis and cell proliferation in the central 
nervous system (CNS) (Griffith & Sutin, 1996). However，the relationship between 
increased TNF-a and p-AR activation remains to be established. Recently, it was 
reported that TNF-a selectively induced the expression ofTNF receptor 2 (TNF-R2) in 
C6 glioma cells (Huang et al.，1998), a receptor responsible for proliferation 
(Bluethmann, 1998) and p-ARs in C6 glioma cells (Lung，1999). 
The above reports suggest that TNF-a might induce astrogliosis and scar 
formation through p-ARs. This study is to further characterize the relationship between 
P-ARs upon TNF-a treatment and the signaling pathway mediating these events in C6 
glioma cells. 
1 
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hi What are the general fwnctioyis of cytokines? 
Communication between cells in the immune and hematopoietic systems is 
mediated by soluble factors called interleukins (IL) or cytokines. 
Cytokines are proteins produced by cells in response to a variety of inducing 
stimuli. They are secreted by their producer cells to influence the behaviour of their 
target cells. Cytokines exert their effects by binding to their specific receptors on the 
surfaces of their target cells. The resulting effects inside the target cell are brought about 
by signal transduction across the plasma membrane (Clemens, 1991) as diagrammatically 
illustrated in Fig. 1. 
bidosM effects 
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Fig. 1 Action of cytokines (abridge from Clemens, 1991). 
2 
、 、 
Chanter 1 TntroHnr^ Vfn 
Most of the physiological roles of the cytokines are related specifically to the 
requirements of multicellular organisms, and are concerned either with co-ordination of 
processes between different cell types, or with the response to environmental stresses. It 
is not surprising, therefore, that many diseases involving disruption of these processes 
are associated with altered regulation of cytokine production and action (Clemens, 
1991). 
Normal cells will generally proliferate in response to specific signals, such as 
cytokines. In addition, cytokines are also concerned with controlling cell growth and 
differentiation (Clemens, 1991). 
Moreover, there are numerous ways in which the immune system responds to 
invasion by foreign organisms or other antigenic agents, and one of the more interesting 
means is the production of cytokines. Since cytokines are produced under appropriate 
circumstances, cells normally do not possess stores of cytokine molecules waiting to be 
secreted in response to a stimulus. Nevertheless, cytokines are produced rapidly by de-
nove synthesis in response to specific stimuli (Clemens, 1991). 
Previously, cytokines were believed to be closely associated with the immune 
system only, however, recently several cytokines and their respective receptors have 
been identified in many organs, e.g., the brain, and cytokines were found in cerebrospinal 
fluid. These observations suggest that cytokines play a key role in mediating 
communication between the nervous and immune systems. One of cytokines in the CNS 
that has drawn much attention these days is TNF-a (Kamei et al, 2000; Wong et a!., 
1996). This is because this cytokine is closely related to brain injury (Fan et a I., 1996; 
Kamei et al., 2000). 
3 
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12 What is TNT-a? 
TNP-a is a 17kD protein produced mainly by activated macrophages in response 
to wide variety of stimuli including mitogens, cytokines, bacteria, viruses and parasites. 
In addition, TNT'-a has been shown to take part in altering vascular endothelial cell 
functions during inflammation (Zhu et al” 2000). These suggest that TNF-a is an 
inflammatory cytokine. TNF-a is also known to stimulate other cell types, such as 
astrocytes, to produce cytokines, including interleukin-1 (DL-l), interleukin-6 (IL-6), 
colony stimulating factors and TNF-a itself (Balkwill, 1995). This further suggests the 
importance of TNF-a in brain function. 
TNF-a exists in its biologically active and physiological form as a homotrimer 
with a molecular mass of 52kDa. Well-diffracting crystals of TNF-a had allowed the 
three-dimensional structure to be determined as shown in Fig, 2 (Balkwill, 1995). The 
shape of the TNF-a homotrimer has the appearance of a triangular cone, or bell, in which 
each of the three subunits has a typical jelly roll-|3 structure and the three subunits are 
arranged edge to face (Fig. 2). 
In the brain, TNF-a derived from cerebral or blood-derived cells, may exert a 
positive regulation on platelet-derived growth factor (PDGF) synthesis in human 
astrocytes (Silberstein et al., 1996). PDGF is a pleiotropic cytokine that acts on many 
different cell types (e.g., fibroblasts; smooth muscle, endothelial and neural cells), and is 
able to stimulate a variety of cellular responses, including proliferation, chemotaxis, actin 
reorganization, and Ca^^ mobilisation (Heldin & Westermark，1990; Raines etal” 1990). 
These reports emphasized the importance of TNF-a (and other cytokines) in normal 
functions and pathological states of the nervous system. 
4 
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Fig.2 The TNF-a molecule. Space-filling model of the TNF-a homotrimer binding to 
three p55 TNF receptors (TNF-Rl) (abridge from Balkwill, 1995). 
13 Actions ofTNF^ cc 
TNF-a production and secretion can be induced in macrophages in response to 
bacterial lipopolysaccharide (LPS) (Nakamura et “/., 1999). In the CNS, TNF-a has 
been shown to activate the endothelium for leukocyte adherence and procoagulation 
activity (by increasing von Willebrand factor and platelet activating factor) that can 
exacerbate ischemic damage in the brain {Pober et al, 1990). Indeed, increased TNF-a 
in the brain and blood in response to LPS appears to contribute to increased brain stem 
thrombosis and hemorrhage (Hallenbeck et aL, 1988; Hallenbeck et al.，1991; Siren et 
al., 1992) and can contribute to increased stroke sensitivity/risk in hypertensive rats 
(Barone et al., 1992). TNF-a is known to stimulate other cell types to produce 
cytokines, including IL-1, IL-6，colony stimulating factor, and TNF-a itself (Aggarwal 
and Vilcek, 1992). Moreover, TNF-a plays a pivotal role in inflammatory processes 
5 
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(Stricter et a!., 1993). It activates neutrophils (Shalaby et al, 1985), increases 
leukocyte-endothelial cell adhesion molecule expression (Pober et al, 1990), and 
increases leukocyte adherence to blood vessels and their subsequent infiltration into the 
brain (Liu et aL, 1994). 
TNF-a has been shown to cause oligodendrocytic damage, suggesting an 
important role of TNF-a in demyelination observed in multiple sclerosis (MS) and 
experimental autoimmune encephalomyelitis (Robbins et cd., 1987; Selmaj and Raine, 
1988; Hofman et aL, 1989). In primary astrocytes, TNF-a increases class I major 
histocompatibility complex (MHC) and intercellular adhesion molecule-1 (ICAM-1) 
expression, and enhances class 11 MHC expression induced by interferon-y (IFN-y) or 
vims (Frohman et cd., 1989; Massa et al., 1987). These indicate that astrocytes can 
function as antigen presenting cells (APCs) within CNS. In peripheral tissues, such as 
pancreatic cells, TNF-a has been shown to induce insulin secretion (Southern et al., 
1990). These illustrate the diverse actions of TNF-a in our body. 
1.4 General functions of TNF-a in astrocytes 
In the brain, TNF-a is secreted by astrocytes, microglia and some neurons. Some 
reports indicate that the primary role for the macrophage-derived cytokine TNF-a acts 
as a growth promoting factor for the astrocytes, such as in the induction of astrocyte 
proliferation (Selmaj et al., 1990). TNF-a has been recently shown to influence neuronal 
progenitor cell proliferation and differentiation (Wong et a!., 1996). Ho^wqt, very little 
is known about the TNF-a postreceptor signal transduction mechanism that leads to 
either cell growth or differentiation. 
6 
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Moreover, TNP-a has found to be an effector molecule of central importance to 
the pathogenesis of many infectious, inflammatoiy and autoimmune disorders (Vassalli, 
1992). In addition to its well-studied activities in the peripheral immune system, TNF-a 
has also been reported to play a key pathogenic role in a range of human 
neuroinflammatoiy diseases, such as MS (Selmaj etal., 1991), bacterial meningitis (Leist 
et aL, 1988)，and cerebral malaria (Grau et al., 1989，Akassoglou et ai, 1997). TNF-a 
has also been implied in the pathogenesis of various immune mediated processes, and is 
the key mediator in septic shock (Tracey et al., 1991). In the last decade, investigations 
also focused on the role of cytokines in traumatic brain injury (Goodman et al. 1990; 
Morganti-Kossmann et aL, 1992; Morganti-Kossmann & Kossmann, 1995; Morganti-
Kossman etal, 1997; Ross et aL, 1994; Shohami et a/., 1999). The important role of 
TNF-a in brain injury is further supported by findings that TNF-a mRNA expression so 
as its protein were increased in the brain after brain injury (Fan et a/., 1996). These 
investigators found that significant increase in TNP-a mRNA expression was observed 
one hour after brain injury. So, the post-traumatic alteration in the gene expression of 
TNF-a may play an important role in both the acute and regenerative responses to CNS 
trauma. 
Little is known about the molecular mechanism responsible for the multiple 
biological activities of TKF-a in CNS trauma. However, the first step，as is the case for 
most polypeptide hormones, is the binding to specific cell-surface receptors which then 
activates a variety of biological signals that lead to different effects of the target cell. 
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TNV-rr. receptors (TNF-Rs) 
The fact that TNF-a receptors (TNF-Rs) are involved in mediating the actions of 
TNF-a is readily supported by the observation that TNF-a binding activity to cell-
surface receptors correlate with cell stimulation (Camussi et al, 1991). At present, both 
high-affinity (Kd 二 0.1 pM) and low-affinity (Ka 二 0.1 ruVI) binding sites had been 
identified (Smith et aL, 1989) having a molecular mass of approximately 300kDa, 
possibly composed of dissimilar subunits (Creasy et al., 1987). These types of the 
TNF-R cDNA have been cloned, indicating the presence of two species of TNF-a 
binding proteins (Schall et al, 1990; Loetscher et al, 1990; Smith & Baglioni, 1989), 
named type 1 (TNF-R 1) (Loetscher et al, 1990; Kohno et al, 1990) and type 2 (TNP-
R2) (Smith et al, 1989; Kohno et al, 1990) receptor (Fig. 3). 
TNF-Rs exist in both bound and free forms. The soluble form of TNF-a receptor 
has been detected in urines of healthy subjects (Engelmann et al., 1990) and in the sera of 
cancer patients (Schall et al., 1990) and is probably a ‘ shed，form of cell receptor. This 
soluble receptor may compete with the cell-surface receptor in the binding of TNF-a, 
thus acting as a physiological inhibitor or competitor. 
Comparison between the human TNF-R 1 and TNP-R2 showed that TNF-R 1 of 
the rat is most conserved in the extracellular domain (70% identity) while the TNF-R2 is 
most conserved in the intracellular domain (73% identity). The weaker homology of the 
extracellular domain may help to explain the species specificity of TNF-R2 (Lewis et al., 
1991). However, there is a complete absence of homology between the intracellular 
domains of the two TNP-Rs, suggesting that they utilize distinct signaling pathways 
(Lewis etal., 1991). 
8 
» Chapter 1 Intrndiiction 
T TNF.R2 
TNF-Rl _ 
K M 誦 l ^ g M K i ^ M i 議 i S l i 麗 議 _ 薩 議 _ _ _ _ 讓 _ _ _ 
Extracellular Q ^ ^ ^ 
Cytoplasmic ^ ^ 
side - ^ ^ ^ _ 幼 她 ® 印 w t 
HOOO^ «Conserved region 
Fig‘ 3 Structures of TNF-a receptors，TNF-Rl and TNF-R2 (abridge from Foxwell et al, 
1992). 
Both TNF-Rs are active in signal transduction and that there is redundancy in the 
flmction of the two receptors. TNF-Rl is the biologically relevant TNF receptor and that 
the binding of TNF-a to TNF-R2 is not sufficient to initiate TNF responses. For 
example, Tartaglia et al (1991) proposed that TNF-Rl mediates a large number of 
diverse TNF-a activities, such as cytotoxicity, manganese superoxide dismutase 
(MnSOD) and nuclear factor-kappa B (NF-KB) induction, while TNF-R2 signals for the 
proliferation of primary thymocytes and T cells. At low concentrations of TNF-a, 
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TNF-a would preferentially bind TNP-R2 since the affinity of TNF-a for TNP-R2 is 
higher than for TNF-Rl (Bluethamann, 1998). 
Most cell types express both TNP-Rl and TNF-R2, but expression of one type of 
receptor usually predominates. For example, epithelial cells predominantly express 
TNF-Rl, whereas myeloid and lymphoid cells predominantly express TNF-R2 
(Hohmann et al., 1989; Ware et al.’ 1991). So, the response of a cell to TNF-a is thus 
profoundly shaped by the type ofTNF-R it predominantly expresses (Dopp et al., 1997). 
1.6 Second messengers induced bv TNF-a 
The mechanism through which TNF-a mediates its numerous activities after 
binding to its cell-surface receptors is poorly understood. This is probably due to the fact 
that the intracellular domains of the two TNF-Rs have no sequence homology to any-
other receptors (except for TNF-Rl and Fas antigen) nor to any known catalytic 
domains of protein kinases (Barbara et al., 1996). 
Some studies showed that when TNF-a binds to TNF-Rl, diacylglycerol (DAG) 
is rapidly produced from membrane phospholipids by the activation of a phospholipase C 
(PLC) which then activates two signaling enzymes, a calcium-independent protein kinase 
C (PKC) and acidic sphingomyelinase (SMase) (Barbara et al., 1996). SMase facilitates 
the breakdown of sphingomyelin to ceramide, a second messenger known to stimulate a 
number of cellular responses, including TNF-a-stimulated apoptosis (Obeid et al., 1993; 
Hannun, 1994). These authors found that following TNF-a activation, SMase 
hydrolysed membrane sphingomyelin to ceramide resulting in the activation of a 
ceramide-activated protein kinase which is capable of phosphorylating a mitogen 
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activated protein (MAP) kinase. The activation of MAP kinase and PKC has been shown 
to be relevant to the functional status of phospholipase A2 (PLA2). P L A 2 is essential for 
the release of arachidonic acid (AA) from membrane phospholipids resulting in 
leukotriene and prostaglandin formation, and is necessary for the formation of platelet-
activating factor which can increase neutrophil transmigration (Kuijpers et al., 1992). 
Another pathway involves the induction of a transcription factor which binds to 
KB-like enhancers, and this mechansim is thought to involve PKC (Barbara et al., 1996)， 
but there is also evidence that other kinases or signaling pathways may also particulate in 
the TNP-a signal transduction (Zhang etaL, 2000). 
1,7 Glial Cells 
As glial cell is one of the major sources of TNP-a in injured CNS，so the 
characteristics, properties and functions of glial cells are briefly discussed follow. The 
first account of neuroglia was cited by Dutrochet in 1824, who noticed the existence in 
the CNS of non-neuronal components made up of spindle-shaped cells which were 
morphologically distinct from neurons. These cells were considered as a form of 
connective tissue within the CNS, and were called 'neuroglia', which means nerve glue. 
There are three classes of nonneuronal cells which make up most of the glial population; 
astrocytes, oligodendrocytes, and brain macrophages, also called microglia (Benveniste, 
1992). The basic properties of oligodendrocytes, microglia and astrocytes are briefly 
described below. 
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1.7.1_Qligodendroglia 
Oligodendrocytes, like astrocytes, arise from neuroepithelial cells. 
Oligodendrocytes arise from the 0-2 A progenitor cells, which are detected at embryonic 
day 21 (in the rat) (Raffet a!., 1983). These progenitor cells can differentiate into either 
fibrous astrocytes or oligodendrocytes, depending on environmental influences. In rats, 
most oligodendrocytes are generated in the period of 7-17 days postnatally, with the 
peak occurring at day 14 (Benveniste, 1992). The most commonly used marker for 
oligodendrocyte identification is galactocerebroside, the major glycolipid of myelin. In 
the setting of brain injury, oligodendrocytes are usually viewed as victims, not a defense 
system. 
The function of the oligodendrocyte is myelin formation in the CNS. Myelin 
wraps around axons, acts as insulation for nerve fibers, and allows for efficient nerve 
impulse conduction (Morell et al., 1980). Cytoplasmic projections extend from the 
oligodendrocyte cell body to wrap around nerve fibers in a spiral fashion. The 
oligodendrocyte is capable of producing many intermodes of myelin simultaneously; in 
rat optic nerve, a single oligodendrocyte can myelinate up to 50 separate axons 
(Benveniste, 1992). 
1.7.2_Brain Macrophages nVficrogHa、 
Virtually all body tissues contain cells competent to act as macrophages, and are 
able to recruit bloodborae macrophages. In the brain tissue, a cell population termed 
‘microglia，has the capacity to cany out phagocytosis after injury. All known phenotypic 
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markers for microglia are shared with other cell types, thus, there are no unique 
microglia-specific antigens (Benveniste, 1992). However, microglia can be identified by 
a number of cell surface antigens which include; immunoglobulin Fc receptors (Peny et 
aL, 1985), type 3 complement receptors (Perry et al, 1985; Giulian & Baker, 1986) and 
32-integrins (Aliyama & McGeer, 1990). They can also be identified by the presence of 
nonspecific esterase (Suckling et aL, 1983). 
The major subtypes of microglia include ramified, ameboid and perivascular 
microglia. Ramified microglia appear as highly branched small cells, with branching 
occurring in all planes. The branching of microglia cell processes is often found around 
neurons，suggesting that there may be a functional significance to this physical 
association. Perivascular microglia are found in the perivascular space，and are thought 
to be more closely related to monocytes than to ramified microglia. They do not have the 
extensive branched appearance of ramified microglia, and their cytoplasm often contains 
cytoplasmic vacuoles with lipid material. Ameboid microglia have a similar morphology 
as perivascular microglia, and can be unipolar or bipolar. In inflammatoiy conditions, it is 
the ameboid microglia that becomes activated and proliferates, ultimately forming 
microglial nodules as seen in patients with viral encephalitis and acquired 
immunodeficiency syndrome (AIDS) dementia complex (Price et al., 1988). 
The major known Unction of microglia is the phagocytosis of cellular debris, 
which may be important for tissue modeling in the developing CNS (Perry & Gordon, 
1988). Also, microglia may be involved with inflammation and repair in the adult CNS 
due to their phagocytic ability, release of neutral proteinases and production of oxidative 
radicals. Microglia processes are incorporated in the layer of astrocytic foot processes of 
the perivascular giia limitans, and thus may contribute to the integrity of the blood brain 
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barrier (BBB) (Lassmann et aL, 1991). Moreover, microglia have been demonstrated to 
express major histocompatibility complex (MHC) antigens upon activation, act as 
antigen presenting cells, secrete a number of immunoregulatory cytokines, and respond 
to cytokine stimulation, suggesting an involvement with immune response within the 
CNS (Benveniste, 1992). 
1.7.3 Astrocytes 
Named for their starry shape, astrocytes have been known since the late 19出 
century. The astroctye is the most abundant cell type in the CNS，outnumbering neurons 
by about 10:1. They are, in reality, a lineage representing a large family of cells that share 
certain biochemical and morphological specialization, while diverging in certain 
functional capabilities. 
Classically, there are two principal types of astrocytes, the protoplasmic and 
fibrous astrocytes, which are classified according to their morphological properties, 
antigenic phenotypes, kinetic development, appearance, and response to the growth 
factors. The protoplasmic astrocytes are characterized by thick, branched processes with 
spiny projections and are localized primarily within the gray matter. The fibrous 
astrocytes, in contrast, consist of relatively long, thin processes with few branches and 
are the predominant type in the white matter. 
In the past，it was assumed that astrocytes serve as little more than passive 
physical support elements for neurons in the CNS. This simple view has given way as 
advances in astrocyte biology have made it possible to understand their functions better. 
It is now clear that astrocytes play important roles in brain development and in the 
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pathology of the nervous system. It has been argued that the brain will never be flilly 
understood without an understanding of the many roles of astrocytes (Kimelberg & 
Norenberg, 1989). 
Fundamentally, there are three biochemical characteristic features that define 
astrocytes in the mammalian CNS. The most important is the cytoplasm inclusion of 6-
to 9-nm intermediate filaments whose major structural component is a 49-kD protein, 
the glial fibrillary acidic protein (GFAP) (Bignami et al” 1972). Recently, other 
biochemical markers in astrocytes are also found, such as glutamine synthetase (GS), the 
calcium binding protein, S-100 (Isobe & Okuyama, 1978; Norenberg & Martinz-
Hemandez, 1979; Moore, 1965; Ghandour et aL, 1981). The presence of these two 
enzymes suggest that astrocytes play important role in glutamate/glutamine metabolism 
and calcium homeostasis in the CNS. 
1.7.3.1 Functions of astrocytes 、 
Along with the great variety of astrocyte types, there is an equal diversity of 
specified functions that can be ascribed to particular astrocytes based upon their position 
relationships within the neuraxia and some of the general functions are: 
a. Homeostasis 
Astrocytes serve to maintain the composition of the fluid in the extracellular 
space of the brain. The homeostatic functions which are most directly pertinent to 
injury are regulation of extracellular K丄 concentration, participation in CO2 
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metabolism, and clearance of neurotransmitter from the extracellular space. 
Astrocytes are involved in several of the mechanisms that modulate local blood supply 
in response to neuronal needs. Finally, astrocytes appear to provide substrates for 
energy metabolism to neurons (Benveniste, 1992). 
b. Contribution to regulation of local blood flow 
As the K+ is derived from neuronal action potentials, it serves as an index of local 
neuronal activity as evidenced by observations that muscular blood vessels dilate 
when bathed in K+(Benveniste, 1992). It has been suggested that astrocytes serve as 
the conduit for the potassium would elicit a faster response to K+ signaling by 
diffiision through the extracellular space (Benveniste, 1992). 
The astrocytic participation in CO2 metabolism results in the delivery of protons 
to the vicinity of endothelial cells, which would trigger the alterations of cerebral 
blood flow. In this interaction, proton concentration serves as a signal of neuronal 
aerobic metabolism, and presumably complements the potassium signal of neuronal 
action potentials (Benveniste, 1992). 
c. Neurotransmitter transport system 
One of the best-studied systems involves the metabolism of y-aminobutyric acid 
(GABA), an inhibitory transmitter, which is metabolized by the enzyme GABA 
transaminase (Hansson et a/.，1984). Astrocytes have a high-affinity uptake system 
and metabolism of GABA, have a high level of GABA transaminase, and are thought 
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to be physically important for removing GABA from synaptic clefts (Schousboe et 
al., 1977; Hertz et al, 1978). Astrocytes are also involved in the metabolism of 
glutamate via the action of glutamine synthetase (Norenberg, 1979). 
d. Mechanical support of neurons 
The astrocyte provides a nonrigid supporting and insulating matrix for neurons. 
Because of their large numbers in the CNS, and the strength of the cytoplasmic 
projections (due to the presence of intermediate filaments within astrocytes), the 
astrocyte provides a supportive framework for nerve cells within the CNS 
(Benveniste, 1992). 
e. Immunocompetent cells in the CNS 
Studies in the past 10 years have demonstrated that astrocytes may be involved in 
immunological events occurring in the brain. The astrocyte, upon stimulation, can be 
induced to express MHC antigens and secrete the cytokines: IL-1, IL-6, TNF-a, and 
colony-stimulating factors; all are molecules that stimulate the growth and 
differentiation of macrophages and lymphoid cells. As such, the astrocyte has several 
important functional characteristics unique to traditional APCs, demonstrating the 
astrocytes' potential to act as immunocompetent cells in the CNS (Benveniste, 1992). 
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f. Guidance of migrating neurons during development 
Migrating neurons use radial glial cells to aid in their placement (Rakic, 1971). 
Radial glia are astrocyte-related cells which appear during brain development，and 
then become transformed, presumably into GFAP-positive protoplasmic astrocytes 
(Schmechel & Rakic, 1979). In vivo, immature migrating neurons will cling closely to 
radial glia, and migrate along them to their final destination. It is thought that radial 
glia express adhesion molecules specific for developing neurons that allow them to 
arrive at their appropriate location in the brain (Choi & Lapham^ 1976; Benveniste, 
1992). 
g. Induction of blood brain barrier (BBB) 
The capillary endothelial cells that make up the BBB are joined by tight junctions; 
as a result, the BBB is virtually impermeable to soluble substances. The CNS 
capillaries are almost completely surrounded by astrocytic end-feet, thus, the 
astrocyte can contribute to the structural integrity of the BBB. Some recent evidence 
also suggests that the formation of tight junctions between the endothelial cells is 
induced by astrocytes contacting the endothelium (Benveniste, 1992). 
h. Astrocytic reaction to injury 
One of the most remarkable characteristics of astrocytes is their vigorous 
response to diverse neurologic insults, a feature that is well-conserved across a 
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variety of different species. The prominence of astroglial reactions in various 
neurologic disorders, such as head injury and infection diseases, the rapidity of the 
astroglial response and the evolutionary conservation of reactive astrocytosis indicate 
that reactive astrocytes fulfill important fiinctions for the CNS (Eddleston & Mucke, 
1993). 
In response to brain injury, astrocytes extend numerous processes to form scar 
tissues a process called reactive gliosis, or astrogliosis. Reactive astrocyte formation is a 
nearly universal reaction to injury in the adult mammalian CNS, but it varies in intensity 
in different regions, A dense scar composed primarily of hypertrophic astrocytes forms 
rapidly at the site of a brain or spinal cord injury. Scar formation is thought to be 
important for recovering the tensile strength of the tissue and to shield intact parts of the 
CNS from secondary injury (Ridet et a!., 1997). The astrocytic scar is very compact, 
which has led to the suggestion that it may act as a physical barrier to axonal growth. The 
role of scar formation in axonal regeneration has, however, been difficult to establish and 
remains controversial (for reviewed see Frisen, 1997 and Ridet et a/.，1997; Pekny etal” 
1999). 
The primary signals triggering the characteristic hypertrophy and increase of GFAP 
in reactive astrocytes have not been identified, but cytokines and trophic factors 
produced by microglia or invading monocytes and polymorphonuclear leukocytes can 
amplify the process (Perry & Gordon, 1988). Moreover, in vitro studies have identified a 
variety of neurotransmitter receptors, such as P-ARs and transporters (Shao & 
McCarthy, 1994)，the high affinity uptake of glutamate, aspartate, GAB A, and taurine, 
and nonsaturable uptake of norepinephrine (NE), dopamine and 5-hydroxytryptamine, 
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have also been characterized in primary astrocyte cultures (Hansson, 1989; Gri伍th 
Sutin, 1996). However, it is not clear whether these neurotransmitter receptors and/or 
uptake systems, with the exception that the P-adrenergic system, has been shown to play 
a significant role in brain injury (Griffith & Sutin^ 1996; Hodges-Salova, et a/.，1996). 
Brain mjury, astrogliosiis and scar formation 
Following brain injury, there are often changes in morphology and shape in 
astrocytes and this process is known as reactive astrogliosis. This reaction is believed to 
be the regenerative outcome of CNS injury. Some of changes observed are hypertrophy 
of the cell bodies and cytoplasmic processes (Eng, 1987; Miller et al., 1986; Norenbery, 
1994) and an increase expression of GFAP (Bignami & Dahl，1976; Schacher et al, 
1977), which culminating to form glial scar. Thus, astrogliosis can be readily measured 
by the increase in GFAP. However, the molecular signals or pathways that trigger the 
transformation of normal astrocytes to reactive astrocytes remain undefined. Recently, 
there is increasing evidence that growth factors (for example, colony stimulating factor), 
cytokines (for example, TNF-a), neurotransmitters (for example, noradrenaline) and 
neuropeptides may be involved (Hodges-Salova et al, 1996). Among these substances, 
TNF-a and noradrenaline have attracted most attention. The possible role of TNF-a in 
this process has been discussed in Section 1,4. 
One piece of the earlier evidence suggesting noradrenaline may be involved is the 
study with C6 glioma cells, which have many properties similar to cultured astrocytes. It 
was reported that the addition of N^ -2'-dibutyryl cyclic adenosine-3，，5'-
monophosphate (dbcAMP), an analogue of cyclic adenosine-35'-monophosphate 
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(cAMP) resulted in an increase in GFAP synthesis and also the number of cells increased 
significantly (Messens & Siegers，1992). cAMP is a well-known mediator of 
noradrenergic mechanism. 
In addition, GFAP immunofluorescence in crushed nerves was reported to be 
dramatically elevated compared with intact optic nerves (Hodges-Salova et aL, 1996). 
More interestingly, p-agonist isoproterenol (ISO) also promoted changes in GFAP in the 
absence of injury, while propranolol, an p-antagonist，suppressed the injury-induced 
GFAP immunoreactivity (Hodges-Salova et a!., 1996). These demonstrated that nerve 
injury caused a significant increase in GFAP immunoreactivity and this mechanism is 
liked mediated through an adrenergic mechanism. 
(3-Adrenergic substances exert their actions by binding to p-ARs, and some of 
their properties are briefly described in Section 1.9. 
1.9 B-Adrenergic receptors (p-ARs) 
p-Adrenergic receptors (pARs) are expressed by astrocytes and three P-
adrenergic receptors, pi-, p2- and P3-ARs, are now known to bind norepinephrine and 
epinephrine, to couple to the Gs stimulatory GTP binding protein, and stimulate adenylyl 
cyclase to produce cAMP. While these three receptors display quite similar overall 
structure and function (Strosberg, 1993), a number of intriguing differences have been 
described, most probably linked to specific amino acid sequence variations of the 
receptors (Strosbery, 1995). 
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1.9.1 The active functional unit: the receptor complex 
The human P-AR genes are situated on the long arm of chromosome 5 and codes 
for an intronless gene product of approximately 1200 base pairs (Johnson, 1998). 
The receptor is a member of the seven-transmembrane family of receptors. It is 
composed of 413 amino acid residues of approximately 46 kDa (Henderson etal, 1990). 
P-ARs have been subdivided into at least three distinct pharmacological and molecular 
subtypes: Pi，p2 and P3 (Johnson, 1998). 
The functional response produced by catecholamine depends on subsequent 
interactions between these components: (i) the catecholamines bind to the receptor and 
convert it to its active form; (ii) the activated receptor interacts closely with the nearby G 
protein, which in turn becomes active; and (iii) the activated G protein in turn activates 
the enzyme adenylate cyclase. The latter, then converts adenosine triphosphate (ATP) to 
cAMP, which acts as an intracellular second messenger (De Biasi, 1990), 
1.9.2 General functions and distribution ofp-AR.s 
Of the 
P-receptors, pi-adrenergic receptors ((31 -ARs) predominate in the heart 
and in the cerebral cortex, whereas Pi-adrenergic receptors (j32-ARs) predominate in the 
lung and cerebellum. However, in many cases, both [31- and P2-AR coexist in the same 
tissue, sometimes mediating the same physiological effect (De Blasi, 1990). 
A third subtype of P-adrenergic receptor has also been identified. This receptor 
has pharmacological properties distinct from those of pi- or P2-AR. Agonists that are 
selective for |33-ARs exist and cause nonshivering thermogenesis in rodents (Strosberg, 
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1995). The role of this receptor in humans remains to be defined. The mRNA for p3-AR 
is selectively expressed in brown adipose tissue in rodents and in newborn humans. 
Message can also be detected in white adipose tissue, but the level of expression is very 
low (Strosberg, 1995). Because of its distinct localization in adipose tissues, it is likely 
that this receptor subtype is highly related to lipid metabolism. 
The brain contains both (31- and p2-ARs, which cannot be differentiated in terms 
of their physiological fiinctions. The density of pl-AR varies in different brain areas to a 
greater extent than does that of P2-AR. It has been suggested that this is due to the high 
density of P2-AR in glia or blood vessels (Strosberg, 1995). 
Interestingly, interactions between P-ARs and cytokines have been reported in 
peripheral tissues. Hetier etal{\99\) and Severn etal{\992) observed that P-adrenergic 
agonists could prevent the lipopolysaccharide (LPS) stimulation of TNF-a production 
by microglia and whole blood cells and THP-1 cells (a kidney cell line). These data 
suggest that P-AR activation might be able to suppress cytokine production in the 
kidney. Indeed, Nakamura et aL (1998) reported that isoproterenol depressed renal IL-
6 and TNF productions under conditions when angiotensin II generation was inhibited. 
But, the mechanisms underlying the abnormal cytokine production in the spontaneously 
hypertensive rat are poorly understood. Moreover, Yoshimura et al. (1997) reported 
that P-agonists inhibit the production of TNF-a and DL-ip by LPS-stimulated human 
peripheral blood mononuclear cells and that the inhibitory effects depend upon the 
elevation of cAMP levels. However, interactions between P-ARs and cytokines are still 
unclear. 
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1.10 Functions of P-ARs in astrocytes 
Though astrocytes have been found to express pl- and p2-AR, the functions of 
p-ARs in astrocytes are still controversial. 
1-lQ.l Regulation of astrogliosis by P-ARs 
Accumulated evidence suggests that P-AR in astrocytes can regulate 
astrogliosis, and some supporting reports are briefly summarized below; 
1,10.1.1. p-ARs are expressed in normal optic nerves and up-regulated after nerve crash 
Astrocytes in culture, as well as in various regions of the mammalian CNS, have 
been shown to express p-ARs (Mantyh et “/.，1995; Salm & McCarthy, 1989; 1992; 
Sutin & Shao, 1992), and Mantyh et al. (1995) also demonstrated that (3-ARs are co-
localized with astrocytes in normal rat, rabbit, and human optic nerves (Mantyh et al., 
1995). Moreover, Hodges-Savola et al. (1996) showed that a marked increase in the 
concentration of (3-ARs 14 days after rabbit optic nerve crush and that Mantyh et al 
(1995) showed that, in rats as well as rabbits，a significant increase in the density of {3-
AR occurred within the first 30 days after nerve transection and sustained for 90 days. 
These studies clearly show that p-ARs are up-regulated, expecially in astrocytes，of 
injured nerves. However, the mechanism is not known. 
24 
^ ： Chapter 1 Tmroduction 
1 10.1.2 Tnjiiry-induced alterations in endogenous catecholamines leads to enhanced p-
AR activation 
Under normal conditions, the BBB should effectively prevent passage of 
physiologically significant amounts of catecholamines from the circulation into the 
parachyma of the brain (Cryer, 1987). However, following head injury/trauma, human 
plasma catecholamine levels increased 4-5 fold (Hamill et aL, 1987) due to BBB 
disruption in the region of the injury (Cancilla et al, 1993). Taken together, such 
alterations could allow substantially elevated levels of endogenous catecholamines 
access to P-ARs at or near the injury site. The resulting increase in the levels and 
availability of noradrenaline at the site of injury would subsequently initiate the sequence 
of events leading to astroglial hypertrophy, cellular proliferation, and scar formation 
(Hodges-Savola et al., 1996). 
1 • 10.1.3 P-AR blockade suppresses glial scar formation 
Recently, Sutin and Griffith (1993) reported that continuous in vivo treatment of 
the p-antagonist propranolol led to a reduction in the GFAP-immunoreactivity intensity 
following ricin-induced motor neuron degeneration in the rat spinal cord. This suggests 
that reactive gliosis in vivo and also the astrocyte hypertrophy could be reduced by J3-
adrenergic antagonists. Moreover, Hodges-Savola et al. (1996) demonstrated that 
propranolol infusion significantly reduced the crush-induced increase in GFAP 
immunofluorescence and also attenuated the concomitant increase in cell numbers within 
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injured nerves. As a result, these investigators suggest that the p-adrenergic mechanism 
is involved in the regulation of astrogliosis after CNS injury. 
1 "10.1.4 P-AR agonists affect the proliferation of astrocytes in normal brain 
Recently, Imura et al. (1999) reported that isoproterenol increased heat shock 
protein 27 (HSP27) and mimicked the expression of small heat shock proteins (sHSPs) 
in reactive astrocytes in vivo. This effect has been observed in both C6 glioma cells and 
primary astrocytes with or without ischemia. The formation of reactive astrocytes in vivo 
seems to depend on the overexpression and reorganization of cytoskeletal proteins, such 
as GFAP and actin (Imura et al., 1999). Previous studies have revealed that sHSP can 
modulate not only actin microfilament dynamics (Lavoie et al, 1993) but also GFAP 
assembly (Nicholl & Quinlan, 1994). P-AR activation has been shown to increase the 
synthesis of GFAP in astrocytes (Segovia et al., 1994) and also to regulate GFAP 
assembly by the phosphorylation of their non-a-helical head domains (McCarthy et al., 
1985; Ralton et al., 1994). These findings suggest that P-AR activation and an increase 
in HSP27 may play an important role in cytoskeletal reorganization, accompanied by the 
formation of gliosis after ischemic injury. These observations also help to explain the 
changes in astrocyte morphology following injury. Moreover, Hodges-Savola et al. 
(1996) demonstrated that j3-AR activation, in the absence of injury, can promote 
astroglial hypertrophy and cell proliferation. They also found that there was a significant 
increase in both GFAP-immunoreactivity and cell number in non-injured nerves inibsed 
with isoproterenol. Interestingly, the magnitude of change in isoproterenol-infused 
nerves was similar to those detected in crushed nerves. These data suggest that |3-ARs 
26 
» Chapter 1 Intrndiiction 
directly influence astrocyte function and that injury-related alterations in the amount 
and/or availability of endogenous catecholamines lead to enhanced P-AR activation in 
astrocytes. 
1.11 Manganese Superoxide Dismutase (MnSOD) 
Evidence presented in the above sections suggests that TNF-a exerted a 
proliferative effect on astrocytes and C6 glioma cells, but TNF-a is cytotoxic to other 
cell types, such as tumor cell lines (Sugarman et aL, 1985). The differential cellular 
sensitivities to TNF-a are not clear at present. In this connection, it is interesting to note 
that Wong et al. (1989) reported that the generation of superoxide radicals (O2') or other 
reactive oxygen species (ROSs) that are capable of damaging cellular components 
(Freeman & Crapo, 1982) and activating the release of certain enzymes, such as 
lysosomal enzymes (Smolen，1984), might be involved in the TOT-a-initiated cytotoxic 
pathway (Jones, 1986). 
O2" and hydrogen peroxide (H2O2) are producing by mitochondria during 
electron transport (Bovens, 1977; Freeman & Crapo, 1982; Forman & Boveris，1982). 
Other intracellular sources of O2' and H2O2 are endoplasmic reticulum, peroxisomes, and 
nuclear and plasma membranes (Freeman & Crapo, 1982). Protection against ROS 
toxicity requires antioxidants, such as glutathione and sulfhydiyl components, the 
H202-removing enzymes cataiase and glutathione peroxidase, and the O2' scavenging 
enzyme superoxide dismutase (SOD) (Hassan, 1988; Touati, 1988; Wong et al” 1989). 
Mitochondria^ a major subcellular source of ROS (Dugan et al‘, 1995; Piantadosi 
& Zhang’ 1996)，may play pivotal roles in apoptosis (Kroemer et al, 1997). MnSOD is 
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an inducible enzyme that plays a crucial role in the oxidative damages caused by 
superoxides and other ROSs in mitochondria under physiological, hypoxia-reperfusion, 
and hyperoxic conditions. The precise mechanism of the induction of MnSOD gene 
expression is not known (Pahan et al, 1999), and much less is known of its relationship 
with elevated cytokines, e.g., TNF-a. 
MnSOD is a superoxide dismutase associated specifically with mitochondria in 
which it captures and reduces free radicals, preventing oxidative damage to 
mitochondria and surrounding organelles. Free radical damage has long been held as a 
key element in promoting neuronal cell death in CNS trauma (Braughler & Hall^ 1989; 
1992; Hall & Braughler，1989; 1993)，whereas, overexpression of MnSOD has been 
shown to prevent neuronal cell death by suppression of peroxynitrite production and 
lipid peroxidation (Keller et al, 1998). MnSOD deficiency may contribute to the 
increase of cytosolic release of cytochrome c and to DNA fragmentation that follows 
(Fujimura et aL, 1999). These support the protective role of MnSOD in cell injury. 
MnSOD expression and increased resistance to cell injury and death have been 
established in several paradigms, including resistance of tumor cells to killing by TNF-a 
(Wong & Goeddel，1988), and from resistance of cardiac myocytes treated with TNF-
a to ischemic injury (Nelson et al., 1995; Keller et al., 1998). Despite such correlations, 
it is not known whether and how MnSOD exerts an anti-apoptotic function in these 
tissues/organs. 
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1111 MnSOD is the target gene of NF-KB 
TNF-a receptor activation results in activation of the transcription factor nuclear 
factor KB (NF-KB) which may serve an antiapoptotic role via the induction of target 
genes MnSOD (Tan et al” 1994). There is an emerging body of evidence implicates a 
consequential role for NF-KB based on its activation in various brain injury paradigms 
(Devary et al, 1993; Meyer et al” 1994; Prasad et al.，1994; Mcintosh & Raghupathi, 
1995; Yang etal, 1995; O'Neill & Kaltschmidt, 1997;Mattson etal, 1997). One of the 
possible target genes of NF-KB activation via TNF-a is that of the antioxidant MnSOD, 
which is upregulated in response to TNF-a in a variety of cell types (Das et al., 1995; 
Wong, 1995; Wong ^^ a/., 1996; Hachiya al, 1997; Isoherranen et al, 1997; Jones et 
aL, 1997). 
1.11.2 Induction of MnSOD bv proinflammatory cytokines in rat primary" astrocytes 
Bacterial lipopoly saccharide (LPS) and proinflammatory cytokines are known to 
induce the degradation of SMase to ceramide in rat primary astrocytes (Pahan et al., 
1998; Singh et al, 1998). It has also been reported that LPS and different cytokines 
induce MnSOD in different peripheral cell types (Wong et al” 1989). Recently, Pahan et 
al. (1999) demonstrated that LPS and some cytokines also induced the activity of 
MnSOD by more than twofold in primary astrocytes. However, the mechanism remains 
to be established. 
Moreover，Wong et al (1989) have also shown that treatment with TNP-a 
induces the expression of mRNA for MnSOD but not for other antioxidant enzymes, 
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such as CuZnSOD, catalase and glutathione peroxidase (Wong & Goeddel，1988). This 
suggests the induction is selective. Furthermore, treatment of kidney cells with IL-1 was 
found to induce the expression of MnSOD (Wong & Goeddel, 1988; Masuda et al., 
1988)’ and to inhibit the cytotoxicity of TNF-a (Holtmann & Wallach^ 1987). Thus, 
MnSOD is likely a candidate for protecting cells from the cytotoxicity of TNF-a. 
1,11,3 SMase and ceramides induce MnSOD in various cell types 
Ceramide has been shown to be an important inducer of apoptosis in different cell 
types (Obeid et a!., 1993; Hannun, 1996). However, Pahan et al. (1999) has reported 
that activation of SMase or addition of ceramide in astrocytes increased the activity of 
MnSOD, and the mRNA level of MnSOD was also induced. 
Therefore, the induction of MnSOD by ceramide suggests that apart from 
transducing an apoptotic signal in the cell, ceramide also induces a protective signal for 
the enhanced elimination of cytotoxic superoxide radicals via induced MnSOD. 
Probably, the degree of ceramide-induced apoptosis is dependent on the level of 
ceramide-induced MnSOD activity: that is the higher the ceramide-induced expression 
of MnSOD activity, the lower the ceramide-induced apoptosis and vice versa (Pahan et 
a/., 1999). Consistent with this idea is the finding of Keller et al. (1998) who reported 
that mitochondrial MnSOD prevented neural apoptosis and reduced ischemic brain 
injury. As TNF-a induces C6 glioma cell proliferation (Liu, 1996)，it is important to 
determine whether MnSOD is a candidate responsible for the anti-apoptotic and/or the 
proliferative effect(s) of TNF-a and the mechanism(s) involved. 
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1.12 Why do we use C6 glioma cells? 
The term glioma describes the group of glial neoplasma including astrocytoma, 
glioblastoma, ependynoma, oligodendroglioma and mixed gliomas，such as 
oiigoastrocytoma. Glioma cells are particularly easy to grow in tissue culture 
(Westermark et al., 1973). Although they may not be perfect representatives in all 
aspects of glioma or glial cells in vivo, the relative ease with such cell lines can be 
established has made them widely used as a model system for studies on the biology of 
glial cells. A number of rat brain tumors induced by N-nitrosomethylurea and consisting 
of more or less differentiated astrocyte-like cells are found to contain S-100 protein, a 
characteristic protein of glial cells. It was shown that injection of newborn rats with these 
cultured tumor cells resulted in a high efficiency of tumor formation (Benda et al” 1968). 
Five morphologically distinct clonal cell strains were established from these tumors, only 
one contains appreciable amounts of S-100, and this is the C6 glioma cell line (Benda et 
al., 1968). 
C6 Glioma cells have provided a useful model to study glial cell properties, glial 
factors and sensitivity of glial cells to various substances and conditions (Kempski et al, 
1992; Vemadakis et al., 1992). As a kind of transformed cell line, the growth 
characteristics of C6 cells are immortal, anchorage independent，loss of contact 
inhibition, high plating efficiency and shorter population doubling time. In addition to its 
homogeneous genetic properties, C6 cells are tumorigenic and angiogenic (Freshney, 
1987). C6 Cells express several glial specific markers, such as S-100, GFAP and GS, the 
markers for astrocytes, as well as CNP, an enzyme marker for oligodendrocytes 
(Kempski et a/., 1992; Vemadakis et a!., 1992). xMoreover, the expression or activity of ‘ 
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these markers in C6 cells could be induced. For instance, CNP is induced by neuron-
derived factors, epidermal growth factor and fibroblast growth factor, whereas GFAP 
and GS are induced by insulin, cyclic AMP, platelet-activating factor, muscle-derived 
factors, chronic P-receptor activation and interleukin-4 (IL-4) (Brodie & Goldreich， 
1994; Brodie & Vemadakis, 1991; Parker et al, 1980). Interestingly, cytokines are 
known to be involved in astrocytic and oligodendrocytic properties expression in C6 
cells of early passages (Brodie & Goldreich^ 1994). 
C6 Glioma cells have been found to respond to several cytokines，such as TNF-
a，IL-6, interferon-y (IFN-y) and IL-4. The growth of C6 glioma cells is stimulated by 
the TNF-a, IL-6 and IFN-y (Munoz-Femandez et al, 1991; Munoz-Femandez & 
Fresno, 1993). In addition, IL-4 exerts a biphasic effect on C6 cell proliferation, 
increasing cell proliferation at concentrations ranging from 10-50 ng/ml, while exhibits 
inhibitory effect at higher concentrations (Brodie & Goldreich, 1994). The inhibition of 
cell proliferation is associated with differentiation of the cells to express astrocytic 
phenotypes as evidenced by morphology, increased GFAP immunoreactivity and 
elevated GS expression (Brodie & Goldreich，1994). rL-4 also induces the secretion of 
nerve growth factor in C6 glioma ceils (Brodie & Goldreich，1994). These results 
suggest that the C6 cell line represents a good cell model for the study of the 
proliferation and differentiation of glial cells in vitro. 
1J3 Aims and Scopes of the project 
The CNS has traditionally been regarded as an immunologically privileged site. 
However, recent findings showed that certain cells of the CNS, particularly astrocytes, 
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are modulated by various cytokines, including TNP-a (Benveniste, 1992). Injury to the 
CNS results in the formation of the glial scar, an astrocytic process closely associated 
with astrocyte proliferation, that obstructs regrowing axons. In fact, a number of /力 vitro 
experiments have shown that astrocyte proliferation can inhibit axon growth (Asher et 
al, 2000). 
Recently, it was found that increased levels of TNF-a were observed in plasma 
and CSF in patients after brain injury, and acute increases in TNP-a mRNA and protein 
expression have also been observed in injured rat brain (Fan et al” 1996; Scherbel etcd,, 
1999). Furthermore, anti-TNF-a-substances, for example，HU-211 or TNF-a binding 
protein, improve the neurological outcome in victims of brain injury (Shohami et la., 
1997). So, TNP-a, produced largely by astrocytes of the injured brain, may play an 
important role in the elevation of TNF-a and astrocytes proliferation, and possibly scar 
formation observed in brain injuiy. Consistent with this thought is the report that 
astrocytes undergo dramatic metabolic and morphologic changes, or commonly called 
"reactive astrogliosis" in response to trauma or other pathological insults in the CNS 
(Hodges-Savola et a!., 1996). In addition, p-ARs have been found to regulate astrocyte 
proliferation and/or astrogliosis (Hodges-Savola et a I., 1996; Sutin & Griffith, 1993). 
So, TNF-a could mediate certain pathological events after brain injury via p-AR 
mechanism. But, the relationship between elevated TNF-a and )3-adrenergic mechanism 
following brain injury is still undefined. As a result, it is important to investigate 
relationship between these events with C6 glioma cells so as to elucidate the signal 
transduction pathway(s) mediating the proliferative effects of TNF-a and P-adrenergic 
mechansim in C6 glioma ceils as well as in astrocytes. Astrocytes are capable of 
synthesize and secrete cytokines and they are the most abundant cell type in the CNS. 
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The long-term goal is to find better therapeutic means to improve the outcome of brain 
injury. 
As diverse intracellular signaling pathways have been proposed to regulate the 
expression of cytokines in peripheral cells and that several second messenger systems 
have been reported to mediate cytokine-induced responses, therefore, in the first set of 
experiments, the intracellular signaling pathways mediating the expression ofTNF-Rs, as 
well as that P-ARs in C6 glioma cells were examined. As PKC has been found to be an 
important signal transduction pathway in brain injury (Zablocka et al.’ 1998) and it is 
also a common second messenger system in many cell types, therefore, this pathway was 
investigated. Moreover, this enzyme has been found in C6 glioma cells (Tsang et al., 
1997). A PKC activator, 12-myristate 13-acetate (PMA) and a specific PKC inhibitor, 
3-{l-[3 (amidinothio) propyl]-3-indolyl}-4-(l-methyl-3-indolyl)-lH-pyrrole-2, 5-dione 
methanesulfonate (Ro-31) (Tsang et al.，1997) were used to study the role of PKC on 
TNF-Rs and P-ARs expression. Moreover, as PKA is also a common second messenger 
system in C6 cells (Messens & Siegers, 1992)，its activator, dbcAMP was used to 
investigate whether PKA is involved between TNF-a and induction of TNF-Rs and p-
ARs expression. 
In the second set of experiments, the relationship between P-ARs and TNF-Rs 
was examined. In this study, different selective P-adrenergic agonists and antagonists 
were examined for their effects on TNF-a and TNF-R expression. 
MnSOD induction has been found to be important for protection against 
oxidative stress, and that MnSOD can block or delay apoptosis (Cai & Jones，1998). 
Since earlier work in our laboratory showed that TNF-a can stimulate C6 proliferation 
(Liu, 1996)，thus, in the third set of experiments, we investigated the effect of TNF-a on 
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the MnSOD expression so as to elucidate the relationship between TNF-a, P-adrenergic 
mechanism and MnSOD expression. As previous findings in our laboratory suggested 
that TNF-a action was mediated through p-AR activation, we examined the effects of 
some P-adrenergic agonists and antagonists on MnSOD expression. Moreover, as 
MnSOD was found to be one of the target genes ofNF-KB (Das etal, 1995; Mattson et 
al., 1995; Wong，1995) and that we found TNF-a induced KF-KB expression (Lung, 
1999)，so the effects of some P-adrenergic agonists and antagonists were also included. 
The major aim of this study is to elucidate the signaling pathway mediating 
astrocyte proliferation, an important step that leads to astrogliosis. Last but not least, it is 
hoped that results obtained would provide valuable information on the regulatory 
mechanisms leading to astrogliosis which should lead to a more effective treatment for 
brain injury. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Cell Ling 
Rat C6 glioma cells were obtained from the American Type Culture Collection 
(U.S.A.). They were originally cloned from a rat glial tumor induced by N-
nitrosomethylurea after a series of alternate culture and animal passages (Benda et al., 
1968). 
- ---：二 .-
2.1.2 Cell Culture Reagents 
2.1.2.1 Complete Dulbecco's modified Eagle medium (CDMEM) 
Dulbecco's modified Eagle medium (DMEM) with glucose and L-glutamine 
was purchased from Gibco BRL (U.S.A.). The powdered DMEM (for 1 litre solution) 
and 3.7 g sodium bicarbonate were dissolved in 1 litre of doubie-distiiled water. The 
medium was adjusted to pH 7.2 and filtered (filter: 0.2 ,LUM, Micro Filtration Systems, 
Dublin, U.S.A.) immediately under suction. Then, heat-inactivated fetal bovine serum 
(HI-FBS; purchased from Gibco BRL, U.S.A.), and antibiotics (penicillin, 10,000 
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U/mL; streptomycin, 10,000 fdg/mL; fungizone, 25 ug/mL; Gibco BRL, U.S.A.) were 
added to make the complete D M E M (CDMEM). The final C D M E M contained 10% 
(v/v) ffl-FBS，100 U/mL penicillin, 100 jj-g/mL streptomycin, and 0.25 ^g/mL 
fungizone. This medium was stored at 4°C until use. 
2.1.2.2 Rosewell Park Memorial Institute (RPMI) medium 
Rosewell Park Memorial Institute (RPMI) medium was prepared almost the 
same as DMEJVI, except that 0.2 g sodium bicarbonate was added. The final complete 一 
RPMI (CRPMI) medium contained 10% (v/v) HI-FBS, 100 U/mL penicillin, 100 
fj-g/mL streptomycin, and 0.25 )_ig/mL fungizone. Because RPMI medium contained 
N-[2-hydroxyethyl]pipera2ine-N'-[2-ethanesulfonic acid] (HEPES) as a buffering 
system, its pH is more stable than DMEM^ hence, the CDMEM was used in the 
maintenance of cell culture, while the CRPMI medium was used for proliferation 
assays. This medium was stored at 4。C until use. 
2.1.2.3 Phosphate buffered saline (PBS) 
Phosphate buffered saline (PBS) was prepared by dissolving 8.18 g sodium 
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chloride, 0.2 g potassium chloride, 0.2 g potassium dihydrogen phosphate and 1.44 g 
sodium hydrogen phosphate in 1 litre of nano-pure water, and the pH of PBS was 
adjusted to 7.4 then autoclaved. 
2.1.3 Recombinant cytokine 
Recombinant mouse tumor necrosis factor-a (TNF-a, specific activity: 6x 10^  
U/mL) was purchased from Boehringer Mannheim Biochemica (Germany). This 
cytokine had been shown to be biological active in C6 glioma cells (Huang et aL, 
1998). It was stored in aliquots at -20。C until use. 
2.1.4 Chemicals for signal transduction study 
2.1.4.1 Modulators of protein kinase C (PKC) 
Protein kinase C (PKC) activator, phorbol 12-myristate 13-acetate (PMA; 
Sigma, U.S.A.) was dissolved in complete culture medium at a final concentration of 
4 |LIM and stored at -20°C until use. PKC inhibitor, 3-{ l-[3-{amidinothio)propyl]-3-
indolyl}-4-(l-methyl-3-indolyl)-lH-pyrrole-2,5-dione methanesulfonate (Ro-31; 
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Calbiochem, U.S.A.) was dissolved in dimethyl sulfoxide (DMSO) at a final 
concentration of 100 jiiM. The dissolved PKC inhibitor was also stored at —20。C until 
use. Both modulators had been shown to be very selective in C6 glioma cells (Tsang 
et al., 1997). 
2.1.4.2 Modulator of protein kinase A (PKA) 
Protein kinase A (PKA) activator, N^-2'-dibutyryl cyclic adenosine-3',5'-
monophosphate (dbcAMP; Sigma, U.S.A.), was dissolved in complete culture 
medium at a final concentration of 100 mM and stored at —20。C until use. 
2.1.4.3 p-Adrenergic agonist and antagonist 
Isoproterenol, an j3-adrenergic receptor (p-AR) agonist, and propranolol, an (3-
AR antagonist, were purchased from Sigma, U.S.A. They were dissolved in double-
distilled water at final concentrations of 250 mM and 10 mM respectively, and stored 
at -20°C until use. 
39 . 
‘ Chapter 7. Mnteri^k rmH 
i) pi-Adrenergic agonist and antagonist 
Dobutamine, an 31-adrenergic receptor (Pl-AR) agonist (Deighton et al., 
1992), and atenolol, an pi-AR antagonist (Koganei et ai, 1995)，were purchased from 
Sigma, U.S.A. They were dissolved in double-distilled water at final concentrations of 
10 m M and 50 mJVl respectively, and stored at -20。C until use. 
ii) p2-Adrenergic agonist and antagonist 
Procaterol, an P2-adrenergic receptor (p2-AR) agonist (Koganei et al, 1995)， 
and ICI 118,551, an p2-AR antagonist (Deighton et al., 1992), were purchased from 
Sigma, U.S.A. They were dissolved in double-distilled water and at a final 
concentration of 10 mM, and stored at -20 °C until use. 
2.1.5 Antibodies 
2.1.5.1 Anti-TNF-receptor type 1 (TNF-Rl) antibody 
Antibody against TNF-receptor type 1 (TNP-Rl, 200 ug/mL), an affinity-
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purified goat polyclonal antibody raised against a peptide corresponding to amino 
acids 26 to 45 mapping at the amino terminus of the TNF-Rl precursor of mouse 
origin, was purchased from Santa Cruz Biotechnology, Inc., U.S.A. According to the 
manufacturer, this antibody only reacts with TNF-Rl of mouse and rat origin by 
Western blotting and immunohistochemistry and is non-reactive with TNF-R2. This 
antibody was stored at 4°C until use. 
2.1.5.2 Anti-TNF-receptor type 2 (TNF-R2) antibody 
Antibody against TNF-receptor type 2 (TNF-R2; 200 |ig/mL), an affinity-
purified goat polyclonal antibody raised against a peptide corresponding to amino 
acids 442 to 461 mapping at the carboxy terminus of the TNF-R2 precursor of mouse 
origin, was obtained from Santa Cruz Biotechnology, Inc., U.S.A. According to the 
manufacturer, this antibody only reacts with TNF-R2 of mouse and rat origin by 
Western blotting and immunohistochemistry and is non-reactive with TNF-Rl. This 
antibody was stored at 4''C until use. 
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2.1.5.3 Anti-pl-adrenergic receptor (Pl-AR) antibody 
Antibody against |3l-adrenergic receptor (Pl-AR; 100 |ig/mL), an affinity-
purified rabbit polyclonal antibody raised against a peptide corresponding to amino 
acids 446 to 464 mapping at the carboxy terminus of the |31-AR precursor of mouse 
origin, was obtained from Santa Cruz Biotechnology, Inc., U.S.A. According to the 
manufacturer, this antibody only reacts with pi-AR of mouse and rat origin by 
Western blotting and immunohistochemistry and is non-reactive with (32- or p3-AR. 
This antibody was stored at 4。C until use. 
2.1.5.4 Anti-P2-adrenergic receptor (p2-AR) antibody 
Antibody against p2-adrenergic receptor (P2-AR; 100 jig/mL), an affinity-
purified rabbit polyclonal antibody raised gainst a peptide corresponding to amino 
acids 399 to 418 mapping at the carboxy terminus of the P2-AR precursor of mouse 
origin, was obtained from Santa Cruz Biotechnology, Inc., U.S.A. According to the 
manufacturer, this antibody only reacts with p2-AR of mouse and rat origin by 
Western blotting and immunohistochemistry and is non-reactive with pi- and P3-AR. 
This antibody was stored at 4°C until use. 
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2.1.5.5 Antibody conjugates 
Goat anti-rabbit biotin conjugate and anti-biotin alkaline phosphatase 
conjugate were supplied by Tropix, Inc. (Massachusetts, U.S.A.). Monoclonal mouse 
anti-goat biotin conjugate (1 iig/mL) was purchased from Sigma, U.S.A. All antibody 
conjugates were stored at 4°C until use. 
2.1.6 Reagents for RNA isolation 
TRIzol reagent (Gibco, U.S.A.) and isopropanol (Promega，U.S.A.) were 
stored at 4。C, while chloroform (AnalaR, England) and ethanol (AnalaR, England) 
were stored at room temperature. 
2.1.7 Rgasents for reverse transcriDtion-polvmerase chain reaction fRT-PCR；) 
Deoxynucleotide mix (dNTP, 10 mM each dNTP), AMY reverse transcriptase 
(25 U/j^L), RNAse inhibitor (50 U/uL), random primer p(dN)6 (2 ug/mL), Tag DNA 
polymerase (produced in E. Coli, 5 U/uL) were purchased from Boehringer 
Mannheim, Germany. All restriction enzymes used in this study were purchased from 
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New England Biolabs, U.S.A. The following chemicals: Tris-
ethylenediaminetetraacetic acid disodium salt (TE) buffer used to reconstitute and 
dilute PCR primers, the TE buffer contained 10 mM Tris (pH 8.0) and 1 mM 
ethylenediaminetetraacetic acid disodium salt (EDTA) were purchased from Sigma, 
U.S.A. 
The sets of specific primers for PCR amplification of the corresponding 
specific cDNAs were purchased from Gibco (Hong Kong) and summarized in Table 1. 
The primers were designed on the basis of previous published data TKF-Rl (Himmler 
et al, 1990), TNF-R2 (Bader et al, 1996)，p-actin (Nudei et al., 1983), pi-AR … 
(Elalouf et al., 1993)，|32-AR (Gocayne et al, 1987)，nuclear factor-icB (NF-KB/p50) 
(Tavares et al., 1998), manganese superoxide dismutase (MnSOD) (Sugino, et al” 
1998人 copper-zinc superoxide dismutase (Cu-ZnSOD) (Sugino et al 1998), TNF-a 
(Kwon et al, 1993), and these oligonucleotides were derived from the sequences of 
the corresponding rat genes and cDNA, with nucleotide positions as indicated in 
Table 1. In addition, the primer sequences were chosen from separate exons of the 
genes so that the RT-PCR product could readily be distinguished from any genomic 
DNA-induced PCR products. Each primer was diluted to 2.5 fjM and stored at -20X 
until use. 
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1 1 Reagents for electrophoresis 
Ten X DNA loading buffer contained 30% (v/v) glycerol, 0.25% (w/v) 
bromophenol blue and 60 mM EDTA (pH 8.5). Ten x Tris-boric acid-EDTA (TBE) 
buffer was prepared by dissolving 108 g Tris base, 55 g boric acid and 7.44 g EDTA 
in 1 L double-distilled water, and the pH was adjusted to 8.3. All of the above 
chemicals were obtained from Sigma, U.S.A. DNA ladder purchased from Bio-Rad 
、 
was used as markers. 
2 1.9 Reagents and buffers for Western blot 
I- Block"^ (highly purified casein)，CSPD® Ready-to-Use substrate solution 
(0.25 mM), Nitro-Block™ (20 x chemiluminescent enhancer), and protein molecular 
weight markers were supplied by Tropix, Inc. (Massachusetts, U.S.A.). Two x 
Loading buffer contained 0.5 M Tris, pH 6.8, 10% (v/v) glycerol, 2% (w/v) SDS, 5% 
(v/v) 2-p-mercaptoethanol and 0.03% (w/v) bromophenol blue. One x Running buffer 
was made up of 0.025 M Tris, 0.19 M glycine and 0.1% (w/v) SDS. Transfer buffer 
contained 39 mM glycine, 48 mM Tris, 0.037% (w/v) SDS and 20% (v/v) methanol. 
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Table 1 Primers used in RT-PCR and the predicted sizes of the PGR products. 
eDNA Primer sequences (5'-3') Nucleotide Amplified PGR 
Amplified Position fragment size 
(bp) 
T N P - R l S e n s e strand; 一 
ACCAAGTGCCACAAAGGAACC 415-435 
Antisence strand: 




ACAGACGTTCACGATGCAGGTG 232-253 252 
P-Actin Sense strand: 
TGAGACCTTCAAC ACCCC AG 2166-2185 
Antisense strand: 
[TTCATGAGGTAGTCTGTCAGGTCC 2343-2366 201 
(31 -AR S ense strand: 
TCGTGTGCACAGTGTGGGCC 533-552 
Antisense strand: 
AAGCGGCGCTCGCAGCTGTCA 774-794 262 
p2-AR Sense strand: 
GCCAGCATCGAGACCCTG 355-372 
Antisense strand: 
TTTGTGCTCTTTCAAGCAGAAC 789-810 456 
NF- Sense strand; 
KB/p50 GAGATTCTGAATCCCCCTGA 4-23 
Antisense strand: 
TTCCAGCCGCTATGTGTAGA 807-826 823 
Cu- Sense strand 
ZnSOD GCCGTGTGCGTGCTGAA 9-25 
Antisense strand: 
TTTCCACCTTTGCCCAAGTCA 371-391 383 
MnSOD Sense strand: 一 
ATTAACGCGCAGATCATGCAG 135-155 
Antisense strand: 
TTTCAGATAGTCAGGTCTGACGTT 594-617 483 
TKF-a Sense strand: 
TCCCAACAAGGAGGAGAAATT 171-192 
Antisense strand: 
I T C A T A C C A G G C J C T T G A G C T C A G 1560-581 1411 
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PBS for preparation of blocking buffer contained 0.058 M sodium hydrogen 
phosphate, 0.017 M sodium dihydrogen phosphate and 0.068 M sodium chloride, and 
blocking buffer was prepared by dissolving 0.2% (w/v) I-Block™ (Tropix, 
Massachusetts, U.S.A.) and 0.1% (v/v) Tween®20 (Sigma, U.S.A.) in PBS. Wash 
buffer was PBS plus 0.1% (v/v) Tween®20, and assay buffer contained 20 mM Tris 
(pH 9.8) and ImM magnesium chloride. 
2-1.10 Other chemicals and reagents 
All other chemicals were purchased from Sigma, U.S.A. 
2.2 Maintenance of rat C6 glioma cell line 
Rat C6 glioma cells were cultured, under aseptic conditions, in CDMEM at 
37。C in a humidified incubator (Mode 2400, Shel-Lab., Inc.) under an atmosphere of 
5% CCV95% air. The cells were sub-cultured after 2 to 3 days in culture, at which 
time they had reached confluence. All subculture procedures were performed under 
aseptic conditions in a culture hood (Biogard hood. Baker Company, Inc.) as follows: 
the medium was discarded, and cells were washed with sterile PBS. The cells were 
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treated with 1 mL of 0.25% (w/v) trypsin (Gibco BRL, U.S.A.) at 37。C for 5 minutes 
and then dispersed by shaking. After washed once with 10 mL CDMEM, the cells 
were adjusted to a cell density of 10^  cells/mL and further cultured in a 75 cm^ culture 
flask (Coming Laboratory Sciences Company, U.S.A.) containing 20 mL CDMEM. 
For long-term storage, 1 mL of cells (ICT cells) suspended in FBS containing 
5% (v/v) dimethyl sulfoxide (DMSO, Sigma, U.S.A.) was stored in liquid nitrogen in 
plastic ampoules (Nunc., Denmark). When required, aliquots were thawed in 
CDMEM at 37。C, subcultured, and cells of passages 18 to 28 were used in this study. 
2.3 RNA isolation 
C6 Cells were seeded on 60 mm culture dishes and cultured with or without 
TNF-a and/or drugs as mentioned in Section 2.2.2. All RNA extraction procedures 
were done at 4°C. Cells were washed twice with 3 mL ice-cold PBS and 1 mL of 
TRIzol reagent was added to each dish. After 5 minutes, cells were scrapped effusing 
a cell scrapper and transferred to an Eppendorf tube, then pipetted up and down 
several times to ensure cell breakage and RNA release. Afterwards, 0.2 mL of 
chloroform was added to each tube and followed by vortexing for 15 seconds. The 
tubes were allowed to stand at room temperature for 3 minutes, and centriftjged at 
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li,900xg for 15 minutes at 4°C. The supernatant was removed and 0.5 mL 
isopropanol was added, the solution was then vortexed thoroughly. The tubes were put 
into a freezer (-20。C) overnight to allow the RNA to precipitate. Then, the tubes were 
centrifuged at ll,900xg for 15 minutes at 4°C, and the pellet in each tube was washed 
with 1 mL 75% ethanol and centrifuged at 7,500xg at 4°C for 5 minutes. The RNA 
pellet was resuspended in 30 \iL nuclease-free water and kept at -70。C until use. 
2.3.1 Measurement of RNA yield 
An aliquot of 4 [xL RNA was mixed with 996 j^L H2O, and the absorbance at 
wavelength 260 nm (A^go) was measured to determine the concentration of RNA. The 
purity was determined by calculating the ratio of the absorbance at wavelength 260 
nm to that at wavelength 280 nm (八：^ /^八細).The yield and purity of RNA were 
calculated by the following equation: 
A—x 40 }ig/)il 
Yield = 
(4/1000)x 103 
Purity 二 A ’V A2so 
All RNA samples were adjusted to 0.5 ^g/jiL, and this RNA concentration 
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was used for all reverse transcription (RT) reactions. 
2.4 Reverse transcription-polymerase chain reaction (RT-PCR) 
One jj.g of total RNA was reverse-transcribed in a 20 j^L reaction mixture 
containing 20 U of AMV reverse transcriptase (Boehringer Mannheim, Germany), 5 
mM M g C l�，1 mM of each dNTP (Boehringer Mannheim, Germany), 40 U of RNAse 
inhibitor (Boehringer Mannheim, Germany), 3.2 jj.g random primer p(dN)6 
(Boehringer Mannheim, Germany), 10 mM Tris/HCl，pH 8.3 and 50 mM KCl. The —-一 一 
mixture was incubated at 25°C for 10 minutes, then 42。C for 60 minutes, heated to 
99。C for 5 minutes and cooled to 4。C for 5 minutes. The RT samples were amplified 
immediately or stored at -20°C. 
PCR was performed in a total volume of 25 \aL consisting of 0.625 to 0.5 jiL 
of RT sample (equivalent to 31.25-125 ng of total RNA), 0.625 U of Taq DNA 
polymerase (Boehringer Mannheim, Germany), 1.5 mM MgCU, 0.2 mM of each 
dNTP (Boehringer Mannheim, Germany), 0.2 .uM of both sense and antisense 
oligonucleotides (Gibco, Hong Kong), 10 mM Tris/HCl, pH 8.3 and 50 mM KCl in a 
PCR machine (GeneAmp PCR system 9700, Perkin Elmer, U.S.A.). The PCR 
conditions were: 94X for 5 minutes, then 25 to 35 cycles of 94。C for 0.5 minutes, 59 
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to 65 °C for 1 minute to 1 minute 15 seconds, 72 °C for 1 minute，followed by a final 
extension of 5 minutes at 72 °C. The sequences of PGR primers (Gibco, Hong Kong) 
were described in Section 2AJ as summarized in Table 1. 
A 5 jiL-aliquot of PGR products was loaded with 6 x loading buffer and 
separated on a 2% (w/v) agarose gel. Each gel was run in 0.5 x TBE buffer at 125V 
for one hour, then stained with 1 ^ig/mL ethidium bromide solution and photographed 
under U Y fluorescence, and the band density of the PGR product was quantified by 
densitometry using the program ImageQuant (Microsoft) by Molecular Dynamics. 
Density of the band from the target gene being analyzed was first normalized by the 
corresponding band from P-actin gene, then the normalized value of the treated 
sample was divided by the normalized value of the control in the same set of 
treatment to obtain a relative density value. The higher densitometry value suggested 
higher gene expression. 
To ensure that all the PGR products were from the amplification of 
corresponding transcripts for the genes of interest，the PGR bands of the predicted 
sizes were flirther checked by restriction enzyme (RE) digestion to see if the PGR 
products contained the predicted restriction sites as described by Huang et al. (1998). 
For RE digestion, 20 {iL of PGR products were digested with RE at 37。C for 4 hours 
and separated on a 2% (w/v) agarose gel. The results of RE digestion of MnSOD and 
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Cu-ZnSOD were shown in the Appendix A, while the other's had been reported 
previously (Huang et a/,, 1996; Lung, 1999).. 
2.5 Western blot analysis 
To determine the receptor protein expression following cytokine and/or drug 
treatment, C6 cells were seeded at 6 x 10"cells/100 mm-diameter dish in 10 mL of 
CDMEM. Cells were cultured at 37°C in a humidified atmosphere of 5% CCV95% 
air. On the next day, the culture medium was replaced with fresh medium. Stock 
solutions of individual cytokines and drugs were prepared in CDMEM and added to 
the culture medium to obtain the desired final concentrations. The time for the 
addition of drugs and/or cytokines was varied in such a way that all plates were 
harvested at •the same time. 
At the time of harvest, the culture medium was removed from the plate and 
cells were washed three times with 5 mL of PBS. One mL of Buffer A was added and 
cells were scrapped with a plastic scraper. Cells from 3 to 4 plates were combined into 
a 15 mL polypropylene centrifuge tube. After centrifligation at l,000xg for 10 
minutes, cell pellets were resuspended in 2 mL Buffer A and stored at -70°C until use. 
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Frozen cells were thawed at room temperature. Rupture of cells was achieved 
with sonication at 5 microns twice for 20 seconds (Soniprep 150, MSE SANYO). 
Membrane and lysate fractions were separated by centrifugation at 46,000xg for 30 
minutes in a Beckman J2-MC centrifuge. The pellets containing membrane-chored 
receptors were resuspended in Buffer A and the protein contents were determined 
according to the method of Lowry et al (1951) using bovine serum albumin as a 
standard. The membrane preparations were stored at -SOT until use. 
Fifteen-twenty |Lig membrane preparations were loaded with 2 x loading buffer 
on a 10 to 15% poly aery lamide gel. The gel was run in 1 x running buffer at lOOV for 
1 1/2 hours. After electrophoresis, the gel, nitrocellulose membrane (Schleicher & 
Schuell) and Whatman filter paper were soaked with transfer buffer. The proteins on 
the gel were then electroblotted onto the nitrocellulose membrane by a semi-dry 
blotting unit (Bio-Rad). The blot was set up as follows: three pieces of Whatman filter 
paper were stacked on the platinum platform of a semi-dry blotting unit, the 
nitrocellulose membrane was placed on top of the filter paper stack, and the gel was 
placed on top of the membrane. Lastly, another three pieces of filter paper were 
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Following protein transfer, the blot was washed with PBS, and incubated in 
blocking buffer for one hour. The primary antibody specific to the protein of interest 
was diluted 1:1000 to 1:5000 in blocking buffer, and the blot was incubated with the 
diluted primary antibody overnight. The nitrocellulose membrane was washed twice 
for 5 minutes in a wash buffer. The biotinated secondary antibody was diluted 
1:10,000 in blocking buffer, and the blot was incubated with the diluted secondary 
antibody for one hour. The nitrocellulose membrane was washed twice each for 5 
minutes in a wash buffer. Anti-biotin alkaline phosphatase conjugate was diluted 
1:20,000 in blocking buffer, and the blot was incubated with the diluted conjugate 
solution for 40 minutes. The nitrocellulose membrane was washed 3 times each for 5 
minutes in a wash buffer，followed by washing twice each for 2 minutes with an assay 
buffer. Two millilitres CSPD® Ready-to-Use substrate solution (Tropix) containing 
1:20 Nitro-Block™ (Tropix) was pipetted on the membrane, and the blot was 
incubated with the CSPD® solution for 5 minutes for the luminescent signal to 
develop. The nitrocellulose membrane was then exposed to a Kodak X-ray (XAR-S) 
film and the relative intensity of each band on the X-ray film was analyzed by 
ImageQuant (Microsoft) software on a densitometry system. The relative intensities is 
significanly changed when having >50% change comparing with control. 
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3. RESULTS 
3.1 Effect of TNF>a on the expression of TNF-receptors fTNF-Rs^ in C6 glinm^i 
££ilS 
Some reports indicated that TNF-a produced by glial cells could play an 
important role during nerve tissue regeneration by stimulating the proliferation of 
glial cells (Selmaj et al., 1990) as well as acting as an autocrine growth factor in 
inducing differentiation of neurons (For example, see Munoz-Femandez et al,, 1991). 
However, very little is known about the TNF-a postreceptor signal transduction 
mechanism that leads to cell growth. Recent studies in our laboratory (Huang et al” 
1998) showed that TNF-a selectively induced the expression of TNF-R2 and that 
using selective TNF-R antibodies, TNF-R2 was found to be responsible for the 
proliferative effect in C6 cells (To，1999), therefore the effect of TNF-a on TNF-R 
expression in C6 cells was studied. Moreover, attempts were made to elucidate the 
signal transduction pathways mediating TNF-a and its receptors expression. 
To determine the effect of TNF-a on TNFR gene expression in C6 cells, the 
mRNA levels of both receptor subtypes were measured by RT-PCR as described in 
Section 2.4, and their protein levels determined by Western blot analysis as described 
in Section 2.5. RT-PCR was used to monitor TNF-R gene expression, as this method 
55 
Chapter 3 Results 
is more sensitive than Northern and other techniques (Huang et al.’ 1998). Western 
blot was applied to see if the proteins were expressed similar to their respective 
mRNA. 
3.1.1 Effect ofTNF-g on TNF-Rl and -R2 mRNA expression in C6 cells 
A time-course experiment on the effect of TNF-a on both TNF-Rl and -R2 
expression was performed. Fig. 4 showed the mRNA levels of TNF-Rl- and -R2 in 
C6 cells after exposure to TNF-a (500 U/mL) for various time intervals. This 
concentration of TNF-a had been need to ensure there is a response at early time, 5 
minutes. The P-actin mRNA was used as an internal standard for equal loading in this 
and other similar studies. For TNF-R2 mRNA level, it was enhanced in cells treated 
with 500 U/mL TNF-a as early as 5 minutes，remained high even after 48 hours, and 
the maximum induction was observed at around 2 hours. Thus, the induction was 
time-dependent. On the other hand, the mRNA levels of TNF-Rl and P-actin were 
relatively constant throughout the study times. This indicates that TNF-a is 
specifically induced TNP-R2 mRNA expression in C6 cells. 
Another point of interest was that the level of TNP-Rl was higher than that of 
TNP-R2 in the control cells (Fig. 4). This suggests that, similar to primary cultured 
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astrocytes (Dopp et a!., 1997)，TNF-Rl was the predominant TNF-a receptor subtype 
in C6 cells. 
3.1,2 The signaling systems mediating TNF-a-indiiced TNF-R2 expression in C^ 
The above study indicated that TNF-R2 expression was selectively up-
regulated by the addition of TNF-a, it was therefore interested to investigate what 
was the signal transduction mechanism mediating this action of TNF-a. In this study, 
the possible roles of the PKC and PKA pathways were concentrate, as both are 
common signaling pathways in many tissues (Padmaperuma et al., 1996; Zablocka et 
a!” 1998). 
3.1.2.1 The involvement ofFKC in TNF-a-imto^d TNF-R2 e邓resskm in C^ cells 
In this study, the effects of a PKC activator, phorbol 12-myristate 13-acetate 
(PMA) and a PKC inhibitor, 3-{l-|>(amiciinothio)prophl]-34ndolyl}-4«<l-methyl-3«^ 
indoiyl>-lH-pyrrole-2,5-dione mehanesulfonate (Ro31), on the induction of TNF-R2 
expression by TNF-a were investigated. These agents were found to be selective 
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activator and inhibitor of PKC in C6 cells (Tsang et al,、1997). 
First, different dosages, 0.0162, 0.162, L62, 16.2 and 162 nM of PMA were 
added to the cultures. The mRNA contents of TNF-Rl, -R2 and P-actin were semi-
quantified by RT-PCR. As shown in Fig. 5’ 1.62 nM of PMA had the most 
pronounced effect on TNF-R2 mRNA expression, but 0.162 nM also produced a v^ry 
similar stimulatory effect. As the concentrations of PMA increased from 1.62 to 16.2 
and 162 nM, the mRNA expression declined then, increased again. The reason of this 
maybe related to the non-specific action or down-regulation of high concentrations of 
PMA (Holtmann & Wallach^ 1987). On the other hand, PMA, at all concentrations 
tested had no effects on the expression of TNF-Rl and p-actin. This result suggests 
that activation o f PKC can increase TNF-R2 expression in C6 cells and that there is 
concentration dependence. 
To ensure the stimulation observed with PMA was specific and that the action 
of TNF-a was mediated through PKC，the inhibitory effect of Ro31 on TNF-a 
induction of TNF-R2 was studied. The dosage effects of Ro31 in the presence and 
absence ofTNF-a on the mRNA levels of, TNF-Rl and -R2 were shown in Fig. 6. C6 
Cells were treated with 10，50，100,200 and 500 nM Ro31 aione for 2 hours (Fig. 6b), 
or in the presence of TNF-a (100 U/mL) for an additional 2 hours, and the mRNA 
levels for both TNF-Rs and g-actin were semi- quantified by RT-PCR as described in 
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M C 5 10 20 30 60 120 2401440 2880 (nttn.) 
l ^ ^gnnmimi ig i igmig i i i gmi ig i i i g i igmmigg i ig i im imgg i 
^ ^ ^ ^ n m n m n m i i n i i i i m i i i i m i m i i i m m ^ i 
1 1.01 0.94 0,90 0.97 0.99 1.10 1.04 0•躲 <184 
.jij^^^miQimQjmQiiiiimmimiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii 
1 5.93 Z02 10,7810.60 l i l 7 20,14 23.55 14,01 
• • • • • • • • • • • • • • I 
Fig. 4 Effect of TNF-a on the levels of TNF-Rl，-R2 ami p-actin mRNA in C6 cells. C6 
Cells were treated with 500 U/mL TNF-a for 5 minutes to 48 hours and the total 
RNA was extracted and followed by RT-PCR as described in the Methods. After 30 
cycles of amplification, a 5-jjL aliquot of the PCR product was electrophoresed on 
a 2% agarose gel, stained with ethidium bromide and photogr^hed. The untreated 
cells (C) served as the control. The sizes, in bp, of tiie PCR products were indicated 
on the right. The BNA markers (M) were also run on the same gel. The amounts of 
the PCR products were semi-quantified by densitometry, and the value below each 
band represents the relative intensity after normalization with respect to that of p-
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P M A 
M C 0.0162 0.162 1.62 16.2 162 (nM) 
1 0.96 0.90 0.93 0.73 0.86 
TNF-R2 j j j j j j j j j j j j j j j j^^^j j j j j j j j^ j j j j l -252bp 
1 0.73 1.90 1.96 0.92 1.70 
p-actin -201bp 
Fig. 5 Effect of PMA on the levels of TNF-Rl, -R2 and p-actin mRNA in C6 cells. C6 
Cells were treated with 0.0162 to 162 nM of PMA for 2 hours and the total RNA 
was extracted and followed by RT-PCR as described in the Methods. The untreated 
cells (C) served as the control. Other details were as described in Fig. 4. Data 
presented are representatives of three separate experiments with similar results. 
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Fig. 4. Two hours pretreatment has been found to have an inhibition effectively 
(Tsang et a!.’ 1997). TNF-a at 100 U/mL had been found to produce maximum 
proliferative effect (Lung, 1999). Ro31 alone did not affect to any significant extent 
the expression of TNF-R2 mRNA at all concentrations of Ro3 Itested (Fig. 6b). 
However, the inhibitory action of Ro31 on the TNF-a induction of TNF-R2 was dose-
dependent, and >50% inhibition were observed with 50 nM of Ro31, and a clear 
inhibition was observed with 10 nM of Ro31 (Fig. 6a). It should be noted that this low 
concentration of Ro31 alone did not decrease TNF-R2 level (Fig. 6b). It is also clear 
that Ro31 did not change levels of TNF-Rl mRNA much in the presence or absence 
of TNF-a (Figs. 6a and 6b). These results, together with the observation that PMA 
activated TNF-R2 expression (Fig. 5), suggest that PKC is involved in mediating the 
induction of TNF-R2 by TNF-a in C6 cells. 
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(a) Ro31 (bM) +TNF-a 
i 1 
M C TNF-a 10 50 100 200 500 
TNF-Rl •322bp 
1 L12 1,12 L17 1.27 1.23 L05 
1 199 1.01 0,66 0,67 0.41 0.48 
B-actin 
(B) M C 10 50 100 200 500 ^ ^ ^ 
1 0.87 0.70 0,74 0,73 0,96 
m B H m m m i g i ^ i i i i p B 
TNF-R2 ^ ^ ^ ^ ^ j U H H l U m i l l ^ -252bp 
1 0.97 恢93 0.82 0,93 1.02 
B-actia j ^ B B H E a i l ^ E S S a i S i l ^ i a l ^ ^ • lOlbp 
Fig. 6 Efifect of Ro31 cm the levels of TNF-Rl, -R2 and P-actm mRNA in the presence or 
absence of TNF-^ in C6 ceils, (a) C6 Cells were treated with 100 U/ml TNF-a 
alone for 2 hours, or pre-trcated with 10 to 500 nM Ro31 for 2 hours before the 
treatment with TNF-a. (b) C6 Cells were treated with 10 to 500 nM Ro31 only for 
4 hours. The untreated cells were served as the control (C). The sizes, in bp, of the 
PCR bands were indicated on 也e right. Other details were as describe as Fig. 4. 
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3.1.2,2 Effect ftfPMA on the TNF-R m m kv^ls in cd!s 
To ensure that the TNF-R expression at the protein level was also affected in a 
manner similar to their respective mBNAs, the effect of PMA on both TNF-Rs was 
examined by Western blot. Fig. 7 showed the protein levels of the TNF-Rl and -R2 in 
C6 cells after exposure to PMA (1.62 nM) for 1 to 48 hours. This concentration was 
adopted as it produced maximum stimulation of TNF-R2 tnRNA expression {Fig. 5). 
Two single bands of about 55 and 75 kDa were obtained, and the molecular masses of 
these bands were about the same as the protein products of the cloned TNF-Rl and 
R2 genes (Brockhaus et a!., 1990). 
After exposure to PMA, the TNF-R2 protein was selectively induced at 24 
hours and reached its optimum at 48 hours. These data indicated that this PKC 
activator could also up-reguiate the protein level of TNF-R2 at 24 and 48 hours (Fig. 
7) as well as that of mRNA (Fig, 5) and suggesting that the induction of both its 
mRNA and protein were coupled. The delay observed with protein expression maybe 
related to the time required for translation. 
On the other hand, PMA, at all time points tested, inhibited the expression of 
TNF-Rl (Fig. 7). The inhibition or decrease in TNF-Rl by PMA was unclear at 
present and deserve fiirther studies in the future. 
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PMA (l,62iiM) 
M C 1 2 4 24 4$ (hours) 
1 iK66 0,97 0,67 (K69 0»59 
1 0,74 a71 0激 1.24 t61 
Fig. 7 Effect of PMA treatment on protein levels of TNF-Rl and -R2 in C6 cells. C6 Cells 
were treated with 1.62 nM PMA for 1，2’ 4，24 and 48 hours. The untreated ceil was 
served as the control (C). Thirty of membrane protein were electrq>horesed in a 
10% polyacrylamide gel and transferred onto a nitrocellulose membrane as 
described in the Methods. The protein bands of interest were detected using 
antibody against TNF-Rl or R2, and the luminescent signal generated was cfetected 
by exposing the membrane to an X-ray film. Protein markers (M) were also run on 
the same gel, and the sizes, in kDa, of protein bands were indicated on the right. 
The amount of the protein in each band was semi-quantified by densitometry, and 
the value below each band represents the relative intensity with reference to the 
respective controls (C). Data presented are representatives of three separate 
experiments with similar results. 
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3.1.2.3 Effect of Ro31 on the TNF-a-induced TNF^R2 protein level in 06 relk 
As PMA induced the expression of TNF-R2 at the protein level, similar 
experiments were performed with Ro31 in the presence and absence of TNF-a. Fig. 8 
showed the TNF-R2 protein level in C6 cells after exposure to Ro31 (200 nM) for 
different time intervals in the presence or absence of TNF-a (100 U/ml) for 4 hours. 
A single band of about 75 kDa was observed in the X-ray film, which is expected 
molecular size of TNF-R2 (Brockhaus et aL, 1990). 
After exposure to Ro31, the TNF-a-induced TNF-R2 protein was suppressed 
when Ro31 was added 2 (decreased from 1.94 to 1.38) or 4 (decreased from 1.94 to 
1.26) hours before the addition of TNF-a (Fig. 8). These data indicated that this PKC 
inhibitor could block the level of TNF-a-induced TNF-R2 protein. Treatment with 
Ro31 for 6 and 8 hours had no effect on TNF-R2 protdn (Fig. 8)‘ Similar experiment 
was also performed on TNF-Rl, however, no effect on its expression was observed 
(data not shown). 
Thus, PKC activator, PMA, enhanced the expressions of both TNF-R2 mRNA 
and protein, and that Ro31 suppressed the TKF-a-mduced TNF-R2 mRNA and 
protein expression. These findings suggest that PKC is involved in mediating the 
induction of TNF-R2 in C6 ceils, 
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2 6 4 S + Ro31 (hours) 
M C 4 4 0 4 0 + TNF^a (hours) 
1 h94 1.38 1.02 1.26 1.24 
Fig. 8 Effect ofRo31 on the TNF-a-induced protein level ofTNF-R2 in C6 cells. C6 Cells 
were treated with Ro3l (200 nM) with or without TNF-a <100 U/ml) for various 
time intervals as indicated. The untreated cells (C) served as the control. Other 
details were as described in Fig. 7. Data presented are representatives of three 
separate experiments with similar results. 
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3.1.2.4 Effect of PKA activator on the levd of TNF-R2 mRNA in r 6 celk 
As a preliminary step to determine the specificity of PKC pathway in the 
TNF-a-induced TNF-R2 expression, the effect of a PKA activator, dbcAMP, on the 
TNF-R2 mRNA level in C6 cells was studied. Fig. 9 showed the effect of different 
dosages dbcAMP on TNF-Rl, -R2 and p-actin mRNA levels. As can be seen, there 
was no clear effect of this PKA activator on both TNF-Rs mRNA expression. Though 
we had not tested the effect of any selective PKA inhibitors on the TNF-a-induced 
TNF-R expression, it is likely that PKA may not be a mediator in the induction of 
TNF-R2 in C6 cells. This is because dbcAMP is a very potent stimulator of PKA 
(Messens & Siegers’ 1992). Oth^r experiments are in progress in our laboratory to 
confirm this point and to determine the possible involvement of other signaling 
pathways in mediating the action of TNF-a on TNF-R2 expression. 
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M C 102 iq4 dbcAMP 
(nM) 
TNF-Rl ^ ^ ^ ^ ^ M H W ^ W ^ ^ ^ I -322bp 
1 1.13 0.88 1.10 0.93 
1 1.12 0,94 1.07 0.84 
B-actin -201 bp 
Fig. 9 Effect of various concentrations of dbcAMP on the levels of TNF-Rl, -R2 and p-
actin mRNA in C6 cells. C6 Cells were treated with 10' to 10^  nM dbcAMP for 2 
hours and the total RNA was extracted and followed by RT-PCR as described in the 
Methods. The untreated cells (C) served as the control. Other details were as 
described in Fig. 4. Data presented are representatives of three separate experiments 
with similar results. 
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3.2 Effect of TNF-g on the expression of and 62>adreneryic rcceptors (pj-
and 82-AEs^ ) in C6 gKoma cdls 
As discussed in the Introduction, 0-adrenergic mechanism, besides TNF-ot, 
has been found to regulate astrocyte proliferation or astrogliosis (Hodges-Savola et a!., 
1996; Sutin & Griffith, 1993). In our laboratory. Lung (1999) found that both TNF-a 
and isoproterenol, an P-AR agonist, induced C6 cell proliferation, so, it is likely that 
be a relationship exists between TNF-a and p-ARs. Thus, we investigated the effect 
of TNF-a on the expression of pi- and P2-AR genes in order to determine which 
receptor subtype(s) is/are responsible for the TNF'-a-induced C6 cell proliferation. 
133-AR was not included in this study as this receptor subtype is mainly expressed in 
adipose tissues (Strosberg, 1995). 
To det^mine the effect of TNF-a on the 3-AR expression in C6 cells, their 
mRNA levels were measured by RT-PCR, and their protein levels by Western blot 
analysis. Moreover, the signal transduction pathways mediating TTMF-a-induced p-AR 
gene expression were also examined. 
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3 2 1 Effect o f T N F ^ on pi-and p2-ARs mRNA expression in C6 celk 
A time-course experiment on the effect of TNF-a on p-ARs expression was 
performed. Fig. 10 showed the mRNA levels of pi- and p2-AR in C6 cells after 
exposure to TNF-a (100 U/ml) for different time intervals. This concentration of 
TNF-a was chosen because it induced maximum proliferation in C6 cells (Lung, 
1999). Both pi- and P2-AR mRNA expression were enhanced in cells treated with 
100 U/ml TNF-a from 5 minutes to 48 hours, and the maximum induction for pi- and 
P2-AR were observed at 30 and 60 minutes, respectively, and then reduced. This 
indicates that both pi- and P2-AR were induced by TNF-a, and that the response of 
pl-AR expression was much enhanced at 5 min. (5.4-fold increase) than that of p2-
AR (2.54-fold). Moreover’ both P-ARs were expressed in the untreated cells (Fig. 10). 
3.2.2 The signaling systems mediating TNF>a>induced pi- and p2-AR expression in 
cells 
The above study (Fig. 10) showed that both pi- and P2-AR expression can be 
up-regulated by TNF-a, we therefore tried to investigate the signaling mechanism 
mediating this event. In this study, the possibility of PKC and PKA pathways were 
70 
‘ Chapter 3 Refniits 
concentrated, as they are common signaling pathways in many cell types. 
3.2.2.1 The invotvement of PKC mechanism between TNF 力 and p-ARs in C6 cells 
In this study, the effects of PMA and Ro-31 on the induction of pi- and 02-
AR expression in the presence and absence of TNF-a were investigated. 
Firstly, the effects of 0.0162, 0.162, 1.62，16.2 and 162 nM of PMA, a PKC 
activator, on the mRNA levels of pi- and P2-AR were studied. The pi- and P2-AR 
. _ .. . . . . — 
mRNA contents were semi-quantified by RT-PCR as described in the Methods. As 
shown in Fig. 11, 1.62 nM of PMA produced the most pronounced stimulatory effect 
on both pi- and p2-AR mRNA expression and higher concentrations of PMA were 
inhibitory. This concentration was also most effective in stimulating TNF-R2 
expression (Fig. 5). This suggests that PKC activation can induce both P-AR mRNA 
expressions. Two other points worthy of mentioning were: (a) p2-AR expression 
appeared to be more sensitive, as (>.162nM of PMA already slightly enhanced its 
expression by �26% ; and (b) that pl-AR expression was very much elevated 10-
fold) with th€ addition of 1.62nM PMA. The reason for the differential sensitivities is 
unclear. 
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M C 5 10 20 30 60 120 240 1440 2880 (MIN.) 
• • • • • • • • • • • • • • • • I 
1 3.97 XSO 5.69 454 4M 5.37 4643.02 
H H H H H H H H H H H H 
1 X54 5.094^ 7M 8.51 6.10 7.91 7,26 6.39 
- H B B M m m i M i i m i 
p-actin - 201bp 
Fig. 10 Time course of exposure to TNF-a on the levels of pi-, P2-AR and p-actm mRNA 
in C6 cells. C6 Cells were treated with 100 U/ml TNF-a from 5 minutes to 48 
hours and the total RNA was extracted and followed by RT-PCR as described in the 
Methods. The untreated cells (C) served as the control. Other details were as 
described in Fig. 4. Data presented are representatives of three separate experiments 
- • — -
with similar results. 
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PMA 
M C 0.0162 0.162 1.62 16.2 162 (^M) 
醒 ： H m i i B B i i i i B i i i i m i 
pl-AK -262bp 
W H H B B H H H H H H H H W H H H 
1 0.70 OM 9,99 eSO 0JS5 
m f l H i m i i i i i 
P2.AR -456bp 
1 0.96 1.26 tn 1,15 (k76 
P^actin *20ibp 
• • • • • • • • • • • • • I 
Fig. 11 Efifozt of various concentrations of PMA on the levels of pi-, P2-AR and p-actin 
mRNA in C6 cells. C6 Cells were treated with 0.0162 to 162 nM of PMA for 2 
hours. The untreated cells (C) swed as the control. Odier details were described in 
Fig. 4. Data presented are representatives of fcee separate experiments with similar 
results. 
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Secondly, the dosage effect of Ro31 on the TNF-a-induced mRNA levels of 
both pi- and P2-AR were studied (Fig. 12a). C6 Cells were treated with 10，50’ 100， 
200 and 500 nM Ro31 for 2 hours before exposure to TNF-a for 2 hours, and the 
mRNA levels for both (3-ARs and P-actin were semi-quantified by RT-PCR. The 
results showed that Rd31 at a concentration as low as 10 nM greatly reduced (>50%) 
the expression of both (3-ARs, and that this inhibitory effect was dose-dependent. 
Moreover, Ro31 alone at all concentrations tested, did not alter the expression of both 
P-AR (Fig. 12b). These results suggest that PKC is involved in the TNF-a-induced 
Pl - and P2-AR gene expression in C6 cells. 
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(a) Ro31 (nM) + TNF-a 
I 1 
M C TNF-a 10 50 100 200 500 
Pl-AR -262bp 
1 11.48 5J57 5.87 7.27 407 2,94 
H P f f U f i p i l l i 
j^BJMBWMiimillliHWHHi 
1 3.29 1.26 1.37 1.12 0.30 0.44 
p-aetin 
-201 bp 
(b ) M C 10 50 100 200 50< ^ ^ 
_ •^ lllllllll^ l^lllll^ llll^ ^^ lll^ lll^ lll^ l^^ llllll^ H 
1 QSt 0.81 0.83 0JS7 132 
H H H H H H H H 
1 0.98 0.96 0,95 0.9g 0.89 
Fig. 12 Effect of various concentrations of Ro31 on the levels of pi-, p2-AR aiKi p-actin 
mRNA in the presence and absence of TNF-a in C6 cells, (a) C6 Cells were treated 
with 100 U/ml TNF-a for 2 hours with or without pre-treated with Ro31 (10 to 500 
nM) for 2 hours, (b) C6 Cells were treated with 10 to 500 nM Ro31 for 4 hours. 
The untreated cells (C) served as the control. The sizes, in bp，of the PCR bands 
were indicated on tiie right. Other detaiis were as described in Fig. 11. Data 
presented are representatives of three separate experiments with similar results. 
75 
、 
Chapter 3 RasnUs 
3.2.2.2 Effect of PMA on theRI-and p2-ARa protdn Icvds in cells 
In order to examine whether the protein levels of both p-AR were affected 
in a similar manner as their mRNAs, the expression of both P-AR proteins were 
analysed by Western blotting following various treatments. Fig. 13 showed the protein 
levels of p i and P-ARs in C6 cells after exposure to PMA (L62 nM) for different 
time intervals. This concentration of PMA was chosen as it produced almost maximal 
effect on mRNA expression (Fig. 11). Two single bands of about 50 and 47 IkDa, 
corresponding to pi- and P2-AR, respectively (Gocayne et a/.，1987: Buckiand et a / .， 
1990; Machida et a/.， 1990), were obtained on the X-ray films.. Comparing the 
densities of the two controls, the protein level of p2-AR was lower than that ofpi-AR, 
and this indicates that pi-AR is the dominant receptor subtype in C6 cells. 
After exposure to PMA, both pi- and P2-AR proteins were induced in 2 hours, 
and an optimum effect was observed at 48 hours. These data indicate that this PKC 
activator can up-reguiate the protein levels of both P-AR. 
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P M A (L62nM) 
M C 1 2 4 24 48 (hours) 
1 0.86 1.28 1.54 1.52 1.58 
1 0.88 1.60 2.01 114 2.58 
Fig. 13 Time course of PMA treatment on the protein levels of pi- and p2-AR in C6 cells. 
C6 Cells were treated with 1.62 nM PMA for 1，2，4，24 and 48 hours. The 
untreated cells (C) served as the control. Thirty \xg of membrane protein were 
electrophoresed in a 10% polyacrylamide gel and transferred onto a nitrocellulose 
membrane. Protein bands of interest were detected by using antibody against pi-
and P2-AR, respectively, and the luminescent signal generated was detected by 
exposing the membrane to an X-ray film. The protein markers (M) were also run on 
the same gel. The sizes，in kDa, of protein bands were indicated on the right. The 
amount of the protein in each band was semi-quantified by densitometry，and the 
value below each band represents the relative intensity with reference to the 
corresponding control. Data presented are representatives of three separate 
experiments with similar results. 
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3.2.2.3 Effect of Rq31 on the TNF^nf-indiir.ftd pi” and P2-AR protein levet^ ip 
Fig. 14 showed the protein levels of the two P-ARs in C6 cells after exposure 
to Ro31 (200 nM) for different time intervals in the presence or absence of TNF-a 
(100 U/ml) for 4 hours. Two single bands of about 50 and 47 kDa, corresponding to 
the molecular weight of pi-and p2-ARs, were obtained on the X-ray films. 
After exposure to Ro31 for various times, both the TNF-a-induced pi- and 
P2-AR proteins were suppressed- It was also clear that the longer the exposure time to 
Ro31 before TNF-a treatment, the greater was the inhibition (Fig. 14). These data 
indicate that this PKC inhibitor could block both TNF-a-induced p-AR protein as 
well as the mRNA (Fig. 12) levels. Ro31 alone，at 6 hours, did not change the levels 
ofboth P-ARs. 
As PMA enhanced the protein expression of both pi- and P2-AR, and that 
Ro31 suppressed the TNF-a-induced pi- and P2-AR protein inductions, it suggests 
that PKC is involved in mediating the induction of both TNF-a-induced pi- and p2-
A R m C 6 cells. 
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2 6 4 8 24 28 + Ro31 (hours) 
M C 4 4 0 4 0 4 0 + TNF-ct (hours) 
B I A R ； 暴 恭 • — 举 — • -50 kDa 
1 1.55 1.2« 1.16 1.22 0.70 0.6S 0.9€ 
P2.AR 
1 1.37 1.00 1.21 0.87 0.98 0.S7 0.93 
Fig. 14 Effect of Ro31 and TNF-a treatments on the protein levels of (31- and p2-AR in C6 
cells. C6 Cells were treated with Ro31 (200 nM) in the presence or absence of 
TNF-a (100 U/ml) for various time intervals as indicated. The untreated cells (C) 
served as the control. Other details were described in Fig. 13. Data presented are 




3.2.2.4 Effect of dbcAMP on the levels of pi > and p2^ARs mRNA in C6 
To ensure the specificity of PKC pathway, the effect of a PKA activator, 
dbcAMP, on the pi- and P2-AR mRNA levels in C6 cells were studied. Figure 15 
showed the effects of different doses of dbcAMP on (31、P2-AR and p-actin mRNA 
levels. As can be seen, there was no clear effect of various concentrations of dbcAMP 
on both pi- and P2-AR mRNA expression. It is therefore suggested that PKA may 
not the mediator in the induction of j31- and p2-ARs in C6 cells. As PMA induced, 
whiie Ro31 inhibited the iiiduction of these proteins and mRNAs by TNF-a, it is very 
likely that one of the major second messengers m^iating the induction is PKC. The 
possible involvement of other messengers is currently under investigation in our 
laboratory. 
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dbcAMP 
M C 1炉 1炉 104 105 ( n 购 
Pl-AR .262bp 
1 1.24 t m h2S 1.17 
im^^ ^^ ^^ ^^ miiniimiingmimniiiiiiniiiiiimiiniiinniiiiiniii^ gmiiimiiiimgniiiiiiiiiiiii 
P2-AR •456bp 
1 t i l 0,94 0.84 0.8S 
Fig. i5 Effect of various ccaicentratioiis of dbcAMP on the levels of pl-, p2-ARs and p-
actin mRNA in C6 cdls. C6 CelJs were treated with 10^  to 10^  nM dbcAMP for 2 
hours, and the mRNA expression monitored by RT-PCR. The untreated cells (C) 
served as the control. Other details were described in Fig. 4. Data pres^ted are 
rqjresentations of three separate experiments with similar results. 
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3.3 Relationship between TOF-R2 and mectiaHsim in C6 cells 
As p-ARs have been found to regulate astrocyte proliferation (Liu, 1996) and 
astrogliosis (Hodges-Savola et a!., 1996; Sutin & Griffith^ 1993)，and that Lung {1999) 
in our laboratory had found isoproterenol induced proliferation in C6 cells, it is quite 
clear that P-adrenergic mechanism participates in C6 cell proliferation. Results 
presented in the previous sections showed that TNF-a induced both p-AR expression 
via its activation of TNF-R2 expression in C6 cells. In this section, we examined 
whether P-adrenergic mechanism had any effect on endogenous TNF-a and TNF-R2 
expression by RT-PCR technique as described in Section 2.4. 
i U E f f e c t s of isQprptgrenol and propranolol on endog^ous T N F a mRNA levels 
in C6 cells. 
C6 cells were exposed to different dosages (0.01 to 10 i^M) of isoproterenol 
for 2 hours, and the endogenous TNF-a mRNA levels were semi-quantified by RT-
PCR (Fig. 16a). We observed that TNF-a was not expressed in the unstimuatled cells. 
The expression of TNF-a mRNA was enhanced by concentrations of isoproterenol 
greater than 0.1 jiM, and a 10-fold stimulation was observed with 10 This 
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stimulation was similar to that with T N F ^ (100 U/ml) (Fig. 16a>. To ensure the 
specificity of involvement of P-adrenergic mechanism, the effect of an 玲-ant昭onist, 
propranolol, in the suppression of TNF-a-induced endogenous T N F ^ expression was 
examined. A clear inhibition was observed with 0.5 pM of propranolol, and there was 
concentration dependent with an optimum effect at 25 ^iM (Fig. 16a). Interestingiy, 
the latter concentration of propranolol was found to be most effective in reducing 
TNF-a-induced proliferation in C6 cells (Liu, 1996). Endogenous TNFkx mRNA 
expression was not detected when C6 cells were treated with propranolol at ail 
concentrations tested (Fig. 16b). This suggests that the P-adrenergic agonist exerts a 
positive regulation on endogenous TNF^x expression in C6 cells. 
3.3.2 Effects of isoproterenol and propranolol on TNF-Rs mRNA levels in C6 c d k 
In this study, C6 cells were exposed to different dosages (0.01 to 10 fiM) of 
isoproterenol for 2 hours, and the levels of both TNF-Rs mRNA expression were 
semi-quantified by RT-PCR (Fig. 17). The expression of TNF-R2 mRNA was 
enhanced by all the concentrations of isoproterenol tested. The increases were likely 
to be dose-dependent despite the relative intensity value with 1 jxM was slightly lower 
than that with 0.1 |iM. Although the stimulation by isoproterenol was lower than that 
83 
..——： Chapter 1 RfifflfUs 
with TNF-a (100 U/ml); nevertheless, an enhancement of TNF-R2 expression of 
greater than five-fold was observed with 10 }iM isoproterenol. Consistent with the 
ievoivement of an ^-adrenergic mechanism, p-antagonist, propranolol, suppressed the 
TNF-a-induced TNF-R2 expression, and a clear inhibition was observed with 0.5 |xM 
of propranolol, with an optimum effect at 25 |aM (Fig. 17a). Interestingly, the latter 
concentration of propranolol was found to be most effective in reducing TNFkx-
induced proliferation in C6 cells (Liu, 1996) as well as TNF-KX-induced TNF-a 
mRNA level (Fig. 16). Propranolol alone, especially at low concentrations, did not 
have any clear effect on TNF-R2 mRNA expression (Fig. 17b). As isoproterenol did 
not affect TNF-Rl expression nor did propranolol in the presence or absence of TNF-
a, these suggest that the P-adrenergic mechanism exert specific regulation on TNF-R2 
expression in C6 cells. 
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(a) Isoproterenol (FIM) Propranolol (^M) + TNF-ki 
i ！ I 1 
M C 0,01 0,1 1 10 TNF-a 0,5 2 10 25 
H H B H H I H H I H H I 
1 2>03 2.02 10.03 9.03 礼20 7Ml l«5i 0,95 
(b) M C 0.5 2 10 25 propranoIoK^ 
Endogenous -4Hbp 
TNF-a 
1 1J6 1.07 1,05 1,29 
m n n i i i i i i i i w B 
Fig. 16 Effects of various concentrations of isoproter邸ol and propranolol on the levels on 
endogenous TNF-a and p-actin mRNA in C6 cells, (a) C6 Cells were treated with 
0.01 to 10 ^iM isoproterenol or 100 U/ml TNF-a for 2 hours, or pre-trsKited with 
propranolol (0.5 to 25 ^M) for 2 hours bdbre exposed to 100 U/ml TNF-a for 
another 2 hours. After 35 cycles of amplification, a 5-^L aliquot of the K R 
product was electrc^horesed on a 2% agarose gel stained with ethidium bromide 
and photographed. The imtreated cells (C) served as the control. Other details were 
as described in Fig. 4. Data presented are representatives of three separate 




(a) Isoproterenol (^M) Propranolol (fiM) + TNF-a 
I 1 i 1 
M C 0.01 Oa 1 10 TNF-a 0«5 2 10 25 
• • • • • • • • • • • • • • • • • • • • I 
1 1,19 1.21 0.97 a93 1.05 IAS tOl 0.99 fL97 
1 2.67 Z57 5.65 9.31 4,28 7.80 8L64 3.16 
miij^jiii^iijiiiiiiiii^ i^^ iisoibp 
Propranolol 
(b) M € 0.5 2 10 25 
TNF-Rl .322bp 
1 IM 0,94 0.86 繊 
TNF-R2 " IS lhp 
1 1,04 0.92 0激 0^2 
IHIilPiMlBH HWI l»limi|HI|liMlf' 11.1 IFIiyiMil •IW_IIWIM_I  丨|_圓_ •l—_IMni_l_l_ MM^MIUI —f__ll_ 
Fig. 17 Effects of various concentrations of isoproter^ol and propranolol cm the levels on 
TNF-Rl, -R2 and P-actin mRNA in C6 cells, (a) C6 Cells were treated witb 0.01 to 
10 |iM isoprc^erenoi or 100 U/ml TNF-a for 2 hours, or pre-treated with 
propranolol (0.5 to 25 ^M) for 2 hours before exposed to 100 U/ml TNF-a for 
another 2 hours. Other details were as described in Fig. 4. Data presented are 
representatives of three separate experiments with similar results. 
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3.3,3 E f fec t s o f Bl^agonist and antagonist on endogenous TNF^ot mRNA eypres5;ion 
in cdis 
Since we observed that TNF-a induced the expression of both pl- and P2-AR 
(Fig. iO), we therefore examined the effects of some selective p-AR agonists and 
antagonists on endogenous TNF-a expression. The aim was to see whether these P_ 
AR mechanisms play differential roles in modulating endogenous TNF-a expression. 
In this study，C6 cells were treated with 5, 10, 50, 100 and 500 nM of an pl-agonist, 
dobutamine (Deighton et aL’ 1992) for 2 hours, and the mRNA levels of both 
endogenous TNF-a and P-actin were semi-quantified by RT-PCR. The TNF-a 
mRNA expression was not detected in untreated ceils, but enhanced in a dose 
dependent manner in cells treated with different concentrations of dobutamine, and 
maximum induction was observed with 500 nM (Fig. 18). On the other hand, the 
expression of P-actin was relatively constant at ail concentr^ons of dobutamine 
tested. This finding suggests that the activation of pl-AR would increase the 
expression of endogenous TNF-a expression in C6 cells. 
To ensure the observations with dobutamine (Fig. 18) indeed reflected the 
involvement of the -adrenergic mechanism in regulating endogenous TNF-a 
expression in C6 cells, the dosage effects of an )31-antagonist, atenolol (Koganei et a!., 
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1995)，in the presence or absence of TNF-a (100 U/mL), on the levels of 
endogeneous TNF-a mRNA were studied (Fig. 19). In this study, C6 cells were 
treated with 50, 100, 500 nM and 1 |iM ofatenoloi for 2 hours then following by the 
addition o f 100 U/ml TNF-a for another 2 hours，and the mRNA levels for 
endogenous TNF-a and ^-actin were semi-quantified by RT-PCR. The TNF-a-
induced endogenous TNF-a mRNA level were suppressed by the addition ofatenoloi 
{by 28% with 50 nM). Complete inhibition w斯 observed with 1 |xM of atenolol. 
Howev^, endogenous TNF-a mRNA expression was not detected in untreated cells 
as well as cells treated with atenoiol alone (Fig. 19b). This finding, taken together 
with the observation that dobutamine induced endogenous TNF-a, suggest that pi-
adrenergic mechanism regulates the expression o f endogenous TNF-a in C6 ceils. 
88 
I Chapter 3 KCTIUS 
Dobtitamine 
M C S 10 50 100 500 (碰） 
Endogenous 
TNF-a ^ Q ^ ^ ^ ^ ^ m ^ m m n m u i n 
1 3,拥 lt93 1X01 17,65 23.31 
B H H H H H H H H H H H I 
Fig. 18 Effect of various concefltrations of dobutamine on the levels of endogenous TNF-ct 
and p-actin mRNA in C6 cells. C6 Ceils were treated with 5 to 500 nM of 
dobutamine for 2 hours’ and total RNA was extracted and followed by RT-PCR 
as described in the Methods. Hie untreated cells (C) served as 也e control. Other 
details were described in Fig. 16. Data presented are representatives of thre« 
separate experiments with similar results. 
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(a) atenolol (nM) + TNF-a 
I 1 
M C TNF>a 50 100 500 1000 
Endogenous E ^ B J I ^ ^ W H B B H M ^ m B H m W H B H H 
T N F ^ m m f c — i B ^ i 細 
1 d.39 4.54 4.97 0,98 
0-actiii 
• s i m m i i i H i i i i H i 
(b) M C 50 100 500 1000 
Endogenous •411bp 
t n f k i j ^ H I H H I H I i m 
I 1.09 1.09 0.91 0.94 
. I H H H H H H H I 
Fig. 19 Effect of various concentrations of atenolol on the levels of endogenous TNF-a and 
p-actin mRNA in TNF-a-treated C6 cells, (a) C6 Ceils were pre-treated with 50 
nM to 1 _ atenolol for 2 hours before exposed to TNF-a (100 U/ml) for another 2 
hours, (b) C6 Cells were treated wilii 50 nM to 1 {aM atenolol for 4 hours. The 
untreated cells (C) served as the control Other details were as described in Fig. 16. 
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3.3.4 Effects of BI-agonist and antagonist on TNF-R2 mRNA expression in C.f, r^]]^ 
Since we observed that TNF-a induced the expression of both (31- and (32-
AR (Fig. 10) and that dobutamine induced (Fig. 18) but atenolol reduced TNF-a-
induced TNF-a expression (Fig. 19), we therefore examined the effects of 
dobutamine, a selective pi-AR agonist, and atenolol, an antagonist, on TNP-R2 
expression. The aim was to see whether TNF-R2 expression was also affected. In the 
first study, cells were treated with different dosages of a selective (31-agonist, 
dobutamine (Deighton et al, 1992), and its effect on TNF-R mRNA expression in C6 
cells examined. Briefly, C6 cells were treated with 5, 10, 50，100 and 500 nM 
dobutamine for 2 hours, and the mRNA levels of both TNP-Rs and P-actin were semi-
quantified by RT-PCR. The TNP-R2 mKNA expression was enhanced in cells when 
treated with dobutamine, and a maximum induction (2.8 folds) was observed with 500 
nM (Fig. 20). An 23-fold increase in TNP-a was observed with this concentration of 
dobutamine (Fig. 18). On the other hand, the expression of TNF-Rl and P-actin were 
relatively constant at all concentrations of dobutamine tested. This finding suggests 
that the activation of p 1-AR can increase the expression of TNP-R2 expression in C6 
cells. 
Next, we examined the effect of exposure time to dobutamine (500 nM) on the 
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levels of TNF-Rl and -R2 mRNA expression in C6 cells. This concentration of 
dobutamine was chosen as it enhanced TNF-a expression by 23 folds (Fig. 18) and 
TNF-R2 expression by 2.8 folds (Fig. 20). An 2.4 folds increase in TNF-R2 mRNA 
was observed in cells treated with 0.5 j iM dobutamine for 30 mins, and peaked at 120 
minutes (4 folds), then declined (Fig. 21). No clear effects on TNF-Rl and P-actin 
expression were observed during the times studied (Fig. 21). This finding suggests 
that the activation of pl-AR increases the expression of TNF-R2 in C6 cells. 
To ascertain that the observations with dobutamine (Figs. 20 and 21) indeed 
reflected the involvement of the (31-adrenergic mechanism in regulating TNF-R2 
expression in C6 cells. The dosage effects of a selective pi-antagonist, atenolol 
(Koganei et al, 1995), in the presence or absence of TNP-a (100 U/ml) on the 
expression of TNF-R2 mRNA were studied (Figs. 22). In this study, C6 cells were 
treated with 50，100, 500 nM and 1 uM of atenolol for 2 hours then followed by the 
addition of 100 U/ml TNF-a for another 2 hours, and the mRNA levels for both TNF-
Rs and p-actin were semi-quantified by RT-PCR. The TNF-a-induced TNF-R2 
mRNA levels were greatly suppressed (-70% with 50 nM atenolol) by the addition of 
atenolol, while the levels of TNP-Rl and P-actin were relatively unaffected (Fig. 22a). 
However, atenolol alone, at all concentrations tested, did not cause any clear changes 




22b). This finding，taken together with the observation that dobutamine induced TNF-
R2 selectively，suggest that (31-adrenergic mechanism regulates the expression of 
TNF-R2 in C6 cells. 
3.3,5 Effects of f32-agonist and antagonist on endogenous TNF-a mRNA in C6 cells 
Besides pl-AR, we also studied the effects of (32-adrenergic mechanism on 
endogenous TNF-a mRNA expression. In this study, C6 cells were treated with 5, 10, 
50，100 and 500 nM of a selective p2-agonist, procaterol (Koganei et al., 1995) for 2 
hours, and the mRNA levels of both endogenous TNP-a and P-actin were semi-
quantified by RT-PCR. The TNF-a mRNA induction was observed with 5 nM 
procaterol, and then slightly declined to almost the control level as the concentrations 
of procaterol increased. However, the levels of P-actin mRNA was relatively constant 
at all concentrations of procaterol tested (Fig. 23). This study suggests that |32-
adrenergic mechanism regulates expression of endogenous TNP-a in C6 cells. 
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M C 5 10 50 100 500 触 utamine 
(nM) 
TNT-Rl _322bp 
1 0.95 0.96 1.09 1.12 1.12 
； j j ^ g ^ m o m m m m m i m m m j i i i i i i i i i m i m 
1 1.16 1.21 1.69 2.26 2.86 
HMHHHBHHHIHHHHHHHBHHHIHHHHBI 
P-actin ... "201 bp 
Fig. 20 Effect of various concentrations of dobutamine on the levels of TNF-Rl, -R2 and 
P-actin mRNA in C6 cells. C6 Cells were treated with 5 to 500 nM of dobutamine 
for 2 hours, and the total RNA was extracted and followed by RT-PCR as described 
in the Methods. The untreated cells (C) served as the control. Other details were as 
described in Fig. 4. Data presented are representatives of three separate experiments 
with similar results. 
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M C 30 60 120 240 1440 (mins.) 
1 0.92 1.11 1.08 1.24 1.16 
H H H H H H H H H H I 
1 2.40 2.53 4.05 3.74 1.71 
Fig. 21 Time course of dobutamine on TNF-R 1, -R2 and P-actin mRNA expression in C6 
cells. C6 Cells were treated with 500 nM dobutamine for 30 minutes to 24 hours, 
and the untreated cells (C) served as the control. The sizes, in bp, of the PCR 
products were indicated on the right. Other details were described in Fig. 4. Data 
presented are representatives of three separate experiments with similar results. 
95 
！ Cliaprt^ r 1 PfSTilrs 
(a ) atenolol ( nM) + TNF-a 
I 1 
M C TNF-a 50 100 500 1000 
1 0.98 0.72 0,SS 1.03 0.88 
TNF-R2 -252bp 
1 11.16 3.34 ZIO 4.22 3.39 
(b) M C 50 100 500 1000 atenok)I 
(nM) 
TNF-Rl -322bp 
1 0.91 0,86 0,92 0,89 
TNF-R2 -252bp 
1 1.14 1.02 1.03 0.98 
(3-actin -201bp 
Fig. 22 Effect of various concentrations of atenolol on the levels of TNF-Rl, -R2 and p-
actin mRNA in TNF-a-treated C6 cells, (a) C6 Cells were pre-treated with 50 nIVI 
to 1 jJ.M atenolol for 2 hours before exposed to TNF~a (100 U/ml) for another 2 
hours, (b) C6 Cells were treated with 50 nM to 1 jj.M atenolol for 4 hours. The 
untreated cells (C) served as the control. Other details were as described in Fig. 4. 
Data presented are representatives of three separate experiments with similar 
results. 
- . 96 
、 Chnptcr ] 
To ensure the observations with procateroi (Fig. 23) indeed reflected the 
involvement of the (32-adrenergic mechanism in regulating endogenous TNF-a 
expression in C6 cells, the dosage effects of a selective (32-antagonist, ICI 118,551 
(Deighton et al., 1992), in the presence or absence of TNF-a (100 U/ml), on the levels 
of endogeneous TNP-a mRNA were studied (Fig. 24). In this study, C6 cells were 
treated with 10 nM, 50 nM, 0.1 jaM and 0.5 }iM of ICI 118,551 for 2 hours then 
followed by the addition of 100 U/ml TNF-a for another 2 hours, and the mRNA 
levels for endogenous TNF-a and (3-actin were semi-quantified by RT-PCR. The 
TNP-a-induced endogenous TNF-a mRNA level were greatly suppressed by the 
addition of ICI 118,551. This antagonist，at 10 nM, reduced the TNF-a-induced 
endogenous TNF-a expression by � 4 8 % and complete inhibition was observed with 
high concentrations (100 and 500 nJVI) of this compound (Fig. 24a). However, ICI 
118,551 alone did not cause any clear changes in the expression of endogenous TNP-
a and (3-actin mRNA at all concentrations tested (Fig. 24b). This finding, taken 
together with the observation that procateroi induced endogenous TNF-a, suggests 
that |32-adrenergic mechanism, similar to that of (31-adrenergic, also regulates the 
expression of endogenous TNP-a in C6 cells. 
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procaterol 
M C 5 10 50 100 500 … 。 
— — ( n l V I ) 
Endogenous J ^ ^ j H ^ i ^ H I M M M S i W M l H i i 
^ ^ ^ S I H I H H B I H B B B B B H H H H I 
1 12.98 10.71 10.28 3.15 2.48 
. • • • • • • • 
B-actin -201bp 
H H H H B H H H H H B H H H H 
Fig. 23 Effect of various concentrations of procaterol on the levels of endogenous TNF-a 
and p-actin mRNA expression in C6 cells. C6 Cells were treated with 5 nM to 0.5 
]u.M of procaterol for 2 hours and the total RNA was extracted and followed by RT-
PCR as described in the Methods. The untreated cells (C) served as the control. 
Other details were as described in Fig. 16. Data presented are representatives of 
three separate experiments with similar results. 
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(a ) I C I 118,551 (nM) + TNF-a 
I 1 
M C TNF-a 10 50 100 500 
妨 雞 敬 ' ^ ^ I H B B B S B B f f i m n B H B B B B H B H I B B m i 
Endogenous ^ ^ ^ ^ M g l ^ l M B H M M B M I H 
TNF-a 
1 9.15 4.79 5.06 0.73 0.84 
P-actin • bp 
H H i i i i H i i i H l i i i l i i i i i i l 
(b ) M C 10 50 100 500 I C I 118,551 
Endogenous 
1 1.16 1.12 1.08 0.99 
6-actin J B ^ j H m H i i l M i f f l W i W t H I B W l P P I P P H W i j i S j S 
Fig. 24 Effect of various concentrations of ICI 118,551 on the levels of endogenous TNF-a 
and p-actin mRNA in TNF-a-treated C6 cells, (a) C6 Cells were treated with 100 
U/ml TNF-a, or pre-treated with 10 nM to 0.5 叫M ICI 118,551 for 2 hours，before 
the treatment of TNF-a for another 2 hours, (b) C6 Cells were treated with 10 nM 
to 1 jjM ICI 118,551 for 4 hours. The untreated cells (C) served as the control. 
Other details were as described in Fig. 16. Data presented are representatives of 
three separate experiments with similar results. 
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3.3.6 Effects of P2-agonist and antagonist on TW-R2 mRNA in C6 cells 
As f32-AR expression was also induced by TNP-a (Fig. 10) and that (32-
agonist stimulated TNF-a expression, while |32-antagonist suppressed TNF-a-
induced TNP-a expression, it would be of interest to test whether selective P2-agonist 
and antagonist affect TNF-Rs expression. In this study, ceils were treated with 
different dosages (5, 10，50, 100 and 500 nM) of a selective P2-agonist, procaterol 
(Koganei et al” 1995) for 2 hours, and its effect on the levels TNF-Rl, -R2 and j3-
actin mRNA in C6 cells was measured by RT-PCR (Fig. 25). The TNF-R2 mRNA 
induction was observed with 5 to 50 nM procaterol (by 2.9 to 2.2 folds, respectively), 
and then declined to the control level as the concentrations of procaterol increased. 
However, the levels of TNF-Rl and (3-actin mRNA were relatively constant at all 
concentrations of procaterol tested. 
A time-course experiment on the effects of procaterol on both TNF-Rs and (3-
actin expression was also performed. Fig. 26 showed the mRNA levels of TNP-Rl 
and R2 after exposure to procaterol (10 nNi) for different time intervals, and a 
maximum induction was observed at around 2 hour and remained relatively high even 
at 24 hours. On the other hand, the effect of this j32-agonist on TNF-Rl was rather 
small. These data suggest that P2-adrenergic mechanism regulates expression of TNF-
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R2, in addition to TNF-a, in C6 cells. 
To ascertain this stimulating result of procaterol, we investigated the effect of 
ICI 118, 551, a selective f32-antagonist (Deighton et al, 1992) on TNF-a-induced 
TNF-R2 expression. In this study, C6 cells were treated with 10 nM, 50 nM, 0.1 )iM 
and 0.5 [xM of ICI 118,551 for 2 hours before the addition of 100 U/ml TKF-a for 
another 2 hours, and the mRNA levels for both TNP-Rs as well as that of P-actin were 
semi-quantified by RT-PCR. The TNF-a-induced TNP-R2 mRNA levels were 
suppressed by the addition of 10 and 50 nM of ICI 118,551 by 20% and 56%, 
respectively, and the maximum inhibition was observed with 500 nM (Fig. 27). 
However, ICI 118,551 also inhibited the expression ofTNP-Rl slightly (Fig. 27). This 
P2-antagonist alone did not cause any significant changes in the expression of TNF-
R l , -R2 and P-actin mRNA at all concentrations tested (Fig. 27b). These results 
suggest that P2-adrenergic mechanism also regulates the induction of TNF-R2 in C6 
cells, but the effect is much less pronounced than that of pl-antagonist (Fig. 22). The 
observation that ICI 118, 551 reduced the expression of both TNF-Rs in the presence 
of TNP-a, but had no effect on the basal of these receptor subtypes is intriguing. The 
question whether this is due to the non-specific effect of this |32-antagonist remains to 
be examined. Another point of interest is that the stimulatory action of procaterol (an 
|32-agonist) was faster than that of dobutamine (an |3l-agonist) (comparing Figs. 21 
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and 26). This would imply that the action of |32-adrenergic mechanism was faster, 
though less effective than that of j31. 
3,4 Effects of TNF-a on the expression of a transcriptional factor nuclear factor 
Kappa B (NF-Kg) m C6 glioma cells 
Results presented in the earlier sections suggest that TNP-a-induced C6 cell 
proliferation by activating TNF-R2 and P-ARs. However, the mechanism leading to 
proliferation in C6 cells is unclear. Since the induction of transcription factor(s) 
and/or early genes are commonly involved in cell proliferation, we therefore, 
examined the effect of TNP-a on INP-KB expression. NF-KB was Tound to be 
activated by several cytokines and neurotrophic factors in a number of cell types 
(Sullivan ei al” 1999)，and particularly by TNF-a (Mattson et al, 2000). Consistent 
with this idea is a recent report which stated that NP-KB had a wide range of functions: 
cytokine production, immune activation, and especially, proliferation and 
differentiation (Lim et al., 2000). In the present study, the p50 subunit of NF-KB was 
measured by RT-PCR. This subunit will form a dimer with the p65 subunit and 
translocates to the nucleus and then binds selectively to genes responsive to NF-KB 
(Mattson et al., 2000). Moreover, the signal transduction mechanism between TNF-a 
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M C 5 10 50 100 500 procateroi 
m ^ H l l l l l l l l l f f j l l l l l B B — M (nM) 
TNF-Rl -322bp 
1 0.93 0.84 0.98 1.04 1.04 
1 2.93 2.62 2.23 1.14 1.18 
Fig. 25 Effect of various concentrations of procateroi on the levels of TNF-Rl, -R2 and p_ 
actin mRNA expression in C6 cells. C6 Cells were treated with 5 nM to 0.5 j^M of 
procateroi for 2 hours and the total RNA was extracted and followed by RT-PCR as 
described in the Methods. The untreated cells (C) served as the control. Other 
details were as described in Fig. 4. Data presented are representatives of three 
separate experiments with similar results. 
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M C 30 60 120 240 1440 (mins) 
TNF-R 1 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ -322bp 
1 1.02 0.81 1.05 1.07 1.03 
1 2.01 2.48 2.99 2.19 1.74 
WBBBBa 场 
Fig. 26 Time course of procaterol treatment on TNF-R 1, -R2 and p-actin mRNA in C6 cells. 
C6 cells were treated with 10 nM procaterol from 30 minutes to 24 hours, and the 
total RNA was extracted and followed by RT-PCR as described m Methods. The 
untreated cells (C) served as the control. Other details were as described in Fig. 4. 




Chapter 1 Results 
(a) IC I 118,551 (nM) + TNF-a 
I 1 
M C TNF-a 10 50 100 500 
TNF-Rl 322bp 
- ^ M B B B B B B W H B B w I ^ ^ ^ ^ B B B B W H 
1 0.98 0.71 0.86 0.78 0.77 
j ^ p i i p i i m u m i m i i m u m i i 
1 1.83 1.45 0.80 1.08 0.23 
g i g g g ^ l l l l l l i m i l l l l l l l H I I I I I I I I H ^ I I ^ I I I i g 
m i a i i i i i i i i i H i H i l H i f 
(b) M C 10 50 100 500 IC I 118,551 
(nM) 
TNF-Rl -322bp 
1 1.09 1.06 1.13 0.98 
1 1.12 1.05 0.98 1.02 
Fig. 27 Effect of various concentrations of ICI 118,551 on the levels of TNF-Rl, -R2 and p-
actin mRNA in TNF-a-treated C6 cells, (a) C6 Cells were treated with 100 U/ml 
TNF-a, or pre-treated with 10 niM to 0.5 /iM ICI 118,551 for 2 hours, before the 
treatment of TNF-a for another 2 hours, (b) C6 Cells were treated with 10 niVl to 1 
M-M ICI 118,551 for 4 hours. The untreated cells (C) served as the control. Other 
details were as described in Fig. 4. Data presented are representatives of three 
separate experiments with similar results. 
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binding and NF-KB expression was also investigated. 
3.4.1 Effect of TNF-a on NF-kR fp50、mRNA expression in C6 cells 
In this study, C6 cells were treated with 100 U/ml TNF-a for different time 
periods: 5 minutes to 48 hours. The mRNA level of NF-KB was semi-quantified by 
RT-PCR. The NF-KB mRNA expression was enhanced in a time-dependent manner in 
cells treated with TNP-a, and the maximum induction (about 7.5 folds) was observed 
at around 2 to 4 hours then declined (Fig. 28). This indicates that NF-KB can be 
induced by TNP-a, and it maybe that this gene participates in the TNF-a-induced 
proliferation of C6 cells. 
106 
Chapter 1 R ⑶ I 丨rs 
M C 5 10 20 30 60 120 240 1440 2880 (min.) 
•、 iM丨 •m f f l i i B l l i B iH i l l i l l H I lHHHHn iW I f fB i lH I imB I 
NF-KB - 823bp 
1 1.60 1.29 3.60 2.63 4.18 7.58 7.69 5.41 2.61 
P-actin - 201bp 
Fig. 28 Time course of the effect of TNF-a on the levels of NF-KLB/p50 subiinit and p-actin 
mRNA in C6 cells. C6 Cells were treated with 100 U/ml TNF-a from 5 minutes to 
48 hours, and the total RNA was extracted and semi-quantified by RT-PCR as 
described in the Methods. After 25 cycles of PGR, a 5-jj.L aliquot of the PCR 
product was electrophoresed on a 2% agarose gel, stained with ethidium bromide 
then photographed. The untreated cells (C) served as the control. Other details were 
as described in Fig. 4. Data presented are representatives of three separate 
experiments with similar results. 
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3.4.2 Effects of B-agonist and antagonist on NF-KB (p50) mRNA expression in r ^ 
cells 
In our laboratory, we have found that both TNF-a and (3-agonist can induce 
the C6 cell proliferation (Liu, 1996; Lung, 1999) and that TNP-a-induced p-AR 
expression (Fig. 10)，this suggests that P-adrenergic mechanism is also closely related 
to C6 cell proliferation. So, it is of interest to investigate whether there is a 
relationship between p-adrenergic mechanism and NF-KB expression in C6 cells. In 
this study, different dosages (0.01，0.1，1 and 10 jiM) of an p-agonist，isoproterenol, 
were used to study its effect on NF-KB mRNA expression in C6 cells, and the mRNA 
levels were semi-quantified by RT-PCR. The expression of NF-KB" mRNA was 
enhanced by about 2 folds when exposed to low concentrations (0.01 to 0.1 UM) of 
isoproterenol, and the induction were reduced when the concentrations of the P-
agonist were further increased (Fig. 29). Moreover, the P-antagonist, propranolol, 
suppressed the TNF-a-induced NP-KB at all doses of propranolol tested, by about 
56% with 0.05 jj.M of propranolol，and almost complete inhibition (back to the control 
level) with 25 ^iM (Fig. 29a). Propranolol alone, at all concentrations tested, did not 
have any significant effects on NP-KB mRNA expression (Fig. 29b). This suggests 
that (3-adrenergic mechanism regulates the expression of this nuclear factor and that is 
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involved in mediating the TNF-a-induced NP-KB expression in C6 cells. 
3.4.3 Effects of PMA and Ro31 on the levels of NF-KB mRNA in C6 cells 
Results described before (Figs. 5^8) revealed that TNF-a exerted its action in 
C6 cells by activating PKC, we, therefore, examined the effects of PMA and Ro31 on 
NF-kB expression. In this study, cells were exposed to 0.0162, 0.162，1.62, 16.2 and 
162 nM of PMA, and its effect on NF-KB mRNA expression was examined. As 
shown in Fig. 30’ 0.0162 nM of PMA, the lowest concentration tested, had the most 
pronounced induction effect (3.2 folds) on NP-KB mRNA expression. As the 
concentrations of PMA increased, the mRNA expression declined, and at 162 nM an 
inhibition was observed. This suggests that the activation of PKC induced NF-KB 
mRNA expression. 
To ensure the effect of PMA is specific, the effect of various doses of Ro31 on 
the levels of TNF-a-induced-NF-KB mRNA expression was studied (Fig. 31). C6 
Cells were treated with 10，50, 100, 200 and 500 nM of Ro31 for 2 hours before the 
exposure to TNF-a (100 U/ml) for 2 hours, and the NP-KB mRNA levels semi-
quantified by RT-PCR. Ro31 reduced the TNF-a-induced NF-KB expression (Fig. 
31a). This inhibitory effect of the PKC inhibitor was dose-dependent, a clear 
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(a) Isoproterenol (|iM) Propranolol (jiM) + TNF-a 
I 1 I 1 
M C 0.01 0.1 1 10 TNF-a 0.5 2 10 25 
⑶ - 823bp 
1 2.24 2.01 1.02 0.87 3.78 1.66 1.41 1.70 1.09 
P-actm _ 201bp 
propranolol 
(b ) M C 0.5 2 10 25 ( _ 
nf-KB m^^^^^mm 
(P50) 
1 1.07 0.86 0.93 0.94 
Fig. 29 Effects of isoproterenol, propranolol and TNF-a on the levels ofNF-KB/p50 subunit 
and p-actin mRNA in C6 cells, (a) C6 Cells were treated with 0.01 to 10 fiM 
isoproterenol, 100 U/ml TNF-a for 2 hours，or pre-treated with propranolol (0.5 to 
25 |j.M) for 2 hours before the addition of 100 U/ml TNF-a for another 2 hours. 
The untreated cells (C) served as the control. The sizes，in bp, of the PCR products 
were indicated on the right. The DNA markers (M) were also run on the same gel. 
Other details were as described in Fig. 28. Data presented are representations of 
three separate experiments with similar results. 
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suppressive effect (28%) was observed with 10 nM of Ro31 and higher inhibitory 
were observed with higher concentrations of Ro31(Fig. 31a). Moreover, Ro31 alone 
did not affect the expression of NF-KB at all the concentrations tested (Fig. 31b). 
These results suggest that PKC is involved in the TNP-a-induced NF-KB gene 
expression in C6 cells. 
3,5 Effects of TNF-g on the expression of manganese superoxide dismnf^isf 
(MnSOD) in C6 giioiDa cells 
As discussed in Section 1.11, an overexpression of MnSOD has been shown to 
prevent neuronal cell death by its suppression of peroxynitrite production and lipid 
peroxidation (Keller et al” 1998). Moreover, TNF-a receptor activation results in 
activation of the NF-KB, which may serve as an antiapoptotic role via the induction of 
target genes MnSOD (Mattson, 1997; Cai & Jones, 1998). These suggest that TNF-a 
action, activation of NF-KB, MnSOD expression and anti-apoptosis are closely 
associated. 
As both TNF-a and isoproterenol induce C6 cell proliferation (Liu, 1996; 
Lung, 1999), we therefore investigated the relationship between TNF-a, P-adrenergic 




M C 0.0162 0.162 1.62 16.2 162 ( _ 
1 3.23 2,89 2,14 2.32 0.61 
p-actin ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ -201 bp 
Fig. 30 Effect of various concentrations of PMA on the levels of NF-KB/p50-subunit and P-
actin mRNA in C6 cells. C6 Cells were treated with PMA (0.0162 nM to 0.162 ^M) 
for 2 hours. The untreated cells (C) served as the control. Other details were as 
described in Fig. 4. Data presented are representatives of three separate experiments 
with similar results. 
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(a) 
Ro31 (nM) + TNF-a 
I 1 
M C TNF-a 10 50 100 200 500 
NF-kB 
(p50) -823bp 




(b) M C 10 50 100 200 500 (碰） 
NF-KB 
(P50) 福 P 
1 0.98 0.95 0.99 1.07 0.81 
B-actin -201 bp 
Fig. 31 Effect of various concentrations of Ro31 on the levels ofNF-icB/pSO subunit and p-
actin mRNA in TNF-a-treated C6 cells, (a) C6 Cells were treated with vanous 
concentrations of Ro31 for 2 hours before exposed to 100 U/ml TNF-a. (b) C6 
Cells were treated with 10 nM to 500 niM Ro31 for 4 hours. The untreated cells (C) 
served as the control. Other details were as described in Fig. 4. Data presented are 
representatives of three separate experiments with similar results. 
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Sections 3.3,2 and 3.3.3 that the activation of PKC and P-adrenergic mechanism 
resulted in the elevation of NF-KB mRNA levels in C6 cells. We also examined the 
signal transduction mechanism between TNF-a and MnSOD expression in these cells. 
Another very important reason is because NF-KB activation induces the expression of 
MnSOD (Mattson, 1997; Cai & Jones，1998). 
To delineate this relationhsip, the effects of various agents (to be described 
below) on the MnSOD gene expression in C6 cells were measured by RT-PCR 
technique as described in Section 2.5. 
3.5.1 Effect ofTNF-g on MnSOD and Cu-ZnSOD mRNAs expression in C6 ce]U 
Besides MnSOD, copper-zinc superoxide dismutase (Cu-ZnSOD) is the other 
enzyme that can capture and reduce free radicals, and preventing the oxidative 
damage in a cell (Wong et al, 1989). As TNF-a had been shown to have no effect on 
Cu-ZnSOD in kidney cells (Wong et al, 1989), we therefore investigated if TNF-a 
also selectively induced MnSOD in C6 cells. 
In this study, cells were exposed to different doses of TNF-a (50, 100，500 
U/mL) for 2 hours, and the levels of MnSOD, Cu-ZnSOD and P-actin mRNA in C6 
cells measured by RT-PCR. As shown in Fig. 32，the MnSOD mRNA level was 
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enhanced at all concentrations of TNF-a tested, with the optimal induction (2.5 folds) 
at 100 U/ml TNF-a. On the other hand, no effects on Cu-ZnSOD and P-actin mRNA 
expression were observed with all concentrations of TNF-a tested (Fig. 32). This 
indicates that MnSOD is selectively induced by TNF-a in C6 cells. As the expression 
of Cu-ZnSOD was not affected, no further study on this enzyme was performed. 
Effects of 6-agoni?>t and B-antaeonist on MnSOD mRNA expression in r 6 
Previous studies in our laboratory found that p-adrenergic mechanism was 
related to C6 cell proliferation (Liu, 1996; Lung, 1999) and that MnSOD was reported 
to be antiapoptotic (Mattson, 1997; Cai & Jones，1998)，it is of interest to examine the 
action of isoproterenol and propranolol on MnSOD expression in C6 cells. In the first 
study，cells were exposed to different doses (0.01, 0.1，1 and 10 |iM) of isoproterenol, 
and its effect on MnSOD mRNA expression were semi-quantified by RT-PCR (Fig. 
33a). The level of MnSOD mRNA was induced by all concentrations of isoproterenol 
tested, and higher levels of induction (about 14 folds) were observed with 0.01 to 1 
•LL?vI then slightly declined with 10 uM. Prior treatment with propranolol (0.5 to 25 
•uJVI) suppressed the TNF-a-induced MnSOD mRNA expression, and there was a 
concentration-dependence (Fig. 33a). At 25 .LLVI, which effectively suppressed C6 cell 
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M C 50 100 500 TNF-g (U/ml) 
M n S O D -483bp 
1 2.09 2.52 2.11 
1 0.86 0.93 1.09 
Fig. 32 Effects of various concentrations of TNF-a on the levels of MnSOD，Cu-ZnSOD 
and p-actin mRNA in C6 cells. C6 Cells were treated with 50 to 500 U/ml TNF-a 
for 2 hours，and the total RNA was extracted and semi-quantified by RT-PCR as 
described in the Methods. The untreated cells (C) served as the control. Other 
details were as described in Fig. 4. Data presented are representatives of three 
separate experiments with similar results. 
116 • 
“ Chapter 3 Resiilr.s 
proliferation (Liu, 1996), the induction was about 52%. However, propranolol alone, 
except at high concentrations, did not have any clear effect on MnSOD mRNA 
expression (Fig. 33b), As TNF-a can induce the expression of P-ARs (Fig. 10)，it is 
quite possible that an P-adrenergic mechanism is involved in mediating TNF-a-
induced MnSOD expression in C6 cells. The issue whether there is a differential 
effect of pi- and p2-adrenergic mechanism in regulating MnSOD expression is 
currently under investigation. 
3 5 3 Effects of PKC activator and inhibitor on the levels of MnSOD mRNA in C6 
cells 
Results presented earlier showed that PKC was involved in the induction of 
TNF-R2 and p-ARs (Figs. 5，6，11 and 12), so it is important to examine whether 
PKC also regulate MnSOD expression in C6 cells. In this study, cells were exposed to 
different doses (0.0162，0.162, 1.62，16.2 and 162 nM) of PMA, and the levels of 
MnSOD mRNA were semi-quantified by RT-PCR (Fig. 34). The level of MnSOD 
mRNA was increased by almost 1 fold with low concentrations (0.0162 and 0.162 nM) 
of PMA, then slightly declined or returned to the control level with higher 
concentrations of PMA. This suggests that activation of PKC induces MnSOD mRNA 
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expression in C6 cells. 
Next, the dosage effects of Ro31, in the presence or absence of TNF-a, on the 
levels of MnSOD mRNA were studied (Fig. 35a). C6 Cells were pre-treated with 10， 
50, 100, 200 and 500 nM Ro31 for 2 hours before exposed to TNF-a for 2 hours and 
the levels of MnSOD mRNA were semi-quantified by RT-PCR. This inhibitory effect 
of Ro31 was dose-dependent, the inhibition was about 35% with 10 nM Ro31 and 
greater suppression was observed with higher concentrations of Ro31. Moreover, 
Ro31 alone did not change the expression of MnSOD at all the concentrations of this 
inhibitor tested (Fig. 35b). These results suggest that PKC is involved in the TNF-a-
induced MnSOD gene expression in C6 cells. 
118 
、 
‘ Chapter 3 Results 
(a) 
Isoproterenol (J_IM) Propranolol (JJ.M) + TNF-a 
I 1 I 1 
M C 0.01 0.1 1 10 TiNF-g 0.5 2 10 25 
S I S S H f l H H H H H H H H H H H H H H H B B f l B E S B 
1 13.67 14.56 14.26 12.97 15.65 10.42 10.25 8.76 7.50 
j ^ m m i m m m i i i i i m u 
p-actin -201 bp 
(b) M C 0.5 2 10 25 PropranoloI(JLIM) 
M n S O D -483bp 
1 1.11 0.93 0.78 0.85 
teBWBBMBWHBMWBMHHHSWBHBmHflBHHH^HiBBBBWlBHBWBmBBWiMBBHBB^MBBIIBWHHBSBB 
Fig. 33 Effects of various concentrations of isoproterenol and propranolol and TNF-a on the 
levels on MnSOD and p-actin mRNA in C6 cells, (a) C6 Cells were treated with 
0.01 to 10 jj.M isoproterenol or 100 U/ml TNF-a for 2 hours, or pre-treated with 
propranolol (0.5 to 25 jjM) for 2 hours before addition of 100 U/ml TNF-a for 
another 2 hours. The untreated cells (C) served as the control. Other details were as 
described in Fig. 4. Data presented are representatives of three separate experiments 
with similar results. 
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M C 0.0162 0.162 1.62 16.2 162 PMA (nM) 
M n S O D -483bp 
1 1.94 1.93 1.65 1.57 0.98 
P-actin 一 2 01 bp 
Fig. 34 Effects of various concentrations of PMA on the levels of MnSOD and P-actin 
mRNA in C6 cells. C6 Cells were treated with 0.0162 to 162 nM of PMA for 2 
hours, and the total RNA was extracted and followed by RT-PCR as described in 
the Methods. The untreated cells (C) served as the control. Other details were as 
described in Fig. 4. Data presented are representatives of three separate experiments 
with similar results. 
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(a) Ro31 (nM) + TNF-a 
I 1 
M C TNF-a 10 50 100 200 500 
M n S O D 
1 2.15 1.40 1.07 1.17 1.01 1.13 
-201 bp 
(b) M C 10 50 100 200 500 
(nM) 
M n S O D 
1 1.03 1.08 0.97 0,82 0.98 
P-actin ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ -201 bp 
Fig. 35 Effects of various concentrations of Ro31 on the levels of MnSOD and p-actin 
mRNA in TNF-a-treated C6 cells, (a) C6 Cells were treated with 100 U/ml TNF-a 
for 2 hours，or pretreated with 10 to 500 nM Ro3i for 2 hours before the addition 
with TNF-a for another 2 hours, (b) C6 Cells were treated with 10 to 500 nM Ro31 
for 4 hours. The untreated cells (C) served as the control. Other details were as 
described in Fig. 4. Data presented are representatives of three separate experiments 
with similar results. 
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4. DISCUSSION AND CONCLUSION 
4.1 Effects of TNF-g on the expression of TNF-receptors (TNF-Rs^ in C6 glioma 
cells 
C6 Glioma cells were used as a model to examine the responses of astrocytes 
to TNF-a, as they respond to cytokines like astrocytes (Munoz-Fermandoz et al., 
1991; Munoz-Fermandoz & Fresno, 1993; Brodie & Goldreich^ 1994). Moreover, 
they are easy to grow in culture and with short population doubling time (Benda et al., 
1968; Westermark et al, 1973). 
It was previously reported many cell types contained both TNF-R 1 and -R2 
(Ware et al., 1991; Barbara et al, 1994; Dopp et al, 1998). In our laboratory, we have 
found that C6 cells (Huang et aL, 1998; Lung, 1999; To，1999) and primary cultured 
astrocytes (Lung et al, unpublished results) also contain both receptor subtypes. As 
•？ 
both the levels of I W - R l mRNA and protein were higher in the untreated C6 cells 
(Fig. 7), it is quite possible that this receptor subtype is the predominant subtype in 
normal (untreated) C6 cells. This finding is in agreement with the report that TNF-R 1 
is the predominant receptor subtype in epithelial cells (Ware et al., 1991) and primary 
astrocytes (Dopp et al., 1997). The lower density of TNF-R2 on the surface of a cell 
does not, however, limit the interaction between TNP-a and TNF-R2, as this receptor 
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subtype has higher affinity for this cytokine (Bluethmann, 1998). Moreover, this 
subtype can be selectively induced (Fig. 4). 
Results from the present study showed that TNF-a selectively induced TNF-
R2 mRNA (Fig. 4), as well as its protein (Fig. 8) expression in a time- and dose-
dependent manner (Fig. 4; Lung, 1999). As TNF-a induces C6 cell proliferation (Liu, 
1996; Lung, 1999; To，1999)，the present findings suggest that this selective induction 
of TNF-R2 is related to C6 cell proliferation. This proposed is in line with the thought 
of Tartaglia and his colleagues (Tartaglia et al, 1991; Tartaglia & Goeddel，1992; 
Tartaglia et al., 1993) who based on their studies with the immune system cells 
suggested that TNF-Rl mediates cytotoxicity, which TNP-R2 enhances mitogenic 
effect. Moreover, the cytotoxic action of TNF-Rl was also observed with Hep-2 cells 
(a cell line derived from human carcinoma of the larynx), U937 (a human 
monoblastoid cell line) (Barbara et al., 1994) and endothelial cells (Stoelcker et aL, 
2000). 
Indeed, To (1999) in our laboratory showed that TNF-R2 antibody, but not 
TNP-Rl antibody, inhibited the proliferative effect of TNF-a in C6 cells. Similar 
finding has been reported in cultured microglia (Dopp et al., 1997). The differential 
roles of these receptor subtypes in response to TNF-a has been clearly demonstrated 
by Shen et al. (1997) in their study with SH-SY 5Y cells (a human neuronal cell line)， 
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where they found that treatment of these cells with antisense oligonucleotides for 
TNF-R2, but not for TNF-Rl, significantly increased cell death due to TNF-a 
treatment. This suggests that TNF-a and TNF-R2 play a protective role by forming 
glial scar following neuronal injury as TNF-a had been shown to be elevated in brain 
injury (Fan et al., 1996; Kamei et al., 2000). The importance of TNF-R2 in cell 
proliferation was clearly demonstrated by To (1999) in our laboratory by using 
selective TNF-R antibodies. In addition to the selective induction of TNF-R2 in nerve 
tissues, TNF-R2 had been found to be specifically increased in brain microvessels in 
mice exposed to experimental cerebral malaria (CM) (Lucas et al., 1997). These 
authors also found that mice deficient in TNF-R2 were not significantly protected 
from experimental CM. 
In short, our findings, together with previous reports (cited above), strongly 
suggest that the selective induction of TNF-R2 by TNF-a is closely related astrocyte 
proliferation, astrogliosis, scar formation and the outcome of brain injury. Moreover, 
this selective induction may offer a protection in certain neurological conditions. 
As PKC is a common second messenger in many cell types, and it has been 
found to be the signal transduction mediating TNF-a actions in a human 
erythroblastoid leukemic cell line, K562 (Zhang et al., 1994), we investigated the role 
of PKC in the TNF-a-induced proliferation in C6 cells. We found that PMA induced 
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both the TNP-R2 mRNA and protein levels in C6 cells (Figs. 5 & 7). Both the TNF-
a-induced TNF-R2 mRNA and protein were suppressed by Ro31, a selective inhibitor 
of PKC in C6 cells (Tsang et al., 1997) (Figs. 6 & 8). This suggests PKC is involved 
in TNF-a-induced TNF-R2 expression. The roles played by different PKC 
isoenzymes in mediating this action of TNF-a in C6 cells had been studied in our 
laboratory. Lung (1999) demonstrated that the increase in PKC-(!； following TNF-a 
treatment was most rapid among the PKC isoforms investigated. Moreover, To (1999) 
in her study of TNF-a and intracellular Ca^^ movement in C6 cells found that TNF-a 
induced the elevation of intracellular free Ca2+ levels in C6 cells, and that A23187, a 
Ca2+ ionophore, induced the expression of TNF-R2 and PKC-y, a Ca^^-dependent 
isoform (Das et a/.，1998). A similar up-regulation ofy isoform message has also been 
reported in gerbil hippocampus after transient cerebral ischemia (Zablocka et al., 
1998). Thus, it is likely that both PKC-丫 and < play more important roles in the 
enhanced expression of TNP-R2 in C6 cells. 
Besides PKC, the possible involvement of PKA in the TNF-R2 expression 
was also studied. Our study showed that dbcAMP, an well-established activator of 
PKA (Messens & Siegers, 1992), did not elevate either TNF-Rl or -R2 mRNA levels 
in C6 cells (Fig. 9). Thus, it is likely that the PKA was not involved in the TNF-a-
induced TNF-R2 gene expression in C6 glioma cells. In addition. Lung (1999) in our 
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laboratory showed that tyrosine kinase (TK) and nitric oxide (NO) inhibitors were 
unable to suppress the TNP-a-induced effect on TNF-R2 expression. Al present, we 
believe that PKC is a major messenger involved in the TNF-a-induced TNP-R2 
expression. As SMase has been shown to mediate TNF-a action (Barbara et al，1996)， 
the involvement of this and other signaling pathways in C6 cells cannot be excluded. 
4，2 Effects of TNF-a on the expression of pi- and p2-adrenergic receptors (pt-
and p2-ARs、in C6 glioma cells 
Besides TNP-a, P-adrenergic mechanism has found to be related to astrocyte 
proliferation, astrogliosis and glial scar formation observed following brain injury 
(Griffith & Sutin, 1996). Recently, Lung (1999) has demonstrated that isoproterenol, 
activated C6 cell proliferation, while propranolol inhibited TNF-a-induced cell 
proliferation. This suggests that TNP-a and (3-adrenergic mechanism are closely 
related to proliferation in C6 cells. Indeed, we found that the addition of TNF-a to C6 
cells resulted in an increase in the pl- and (32-AR mRNA levels in a time- (Fig. 10) 
and dose-dependent manner (Lung, 1999). Both p-AR mRNA levels were enhanced 
in 5 minutes and that pl- and P2-AR reached their optima after 30 and 60 minutes, 
respectively, following exposure to TNF-a. It seems that the response of pi-AR 
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expression (5.4 folds at 5 mins.) to TNF-a was faster than that of |32-AR (Fig. 10). 
Both pi- and p2-AR mRNAs were expressed in C6 cells, this suggests that both p-
ARs co-exist in C6 cells, and this is in agreement with the other studies with C6 cells 
(Hough & Chuang, 1990; Zhong & Minneman^ 1993). Furthermore, the decrease in 
both P-AR mRNA levels after 24 hours maybe due to the prolonged, but negative 
action of TNF-a. Although we had not examined whether this induction is also 
mediated through the activation of TNF-R2, based on our findings that both TNF-a 
(Fig. 4) and isoproterenol (Fig. 16) induced the expression of TNF-R2, and that both 
agents induced cell proliferation (Lung, 1999)，it is likely the result observed is 
mediated through TNF-R2. (We are currently investigating this issue using specific 
TNF-Rl and -R2 antibodies.) 
As TNF-a induced the expression of both (3-AR mRNA in C6 cells and that 
the induction of TNF-R2 was mediated by PKC (Figs. 5-8), we studied if PKC is the 
mediator in the TNF-a-induced p-AR. The treatment of PMA resulted in an increase 
in the expression of both (31- and P2-AR mRNA as well as the protein levels in C6 
cells (Figs. 5 and 7), and maximum expression of both proteins was observed at 48 
hours (Fig. 7). Furthermore, TNF-a-induced (31- and P2-AR mRNA and protein 
expressions were suppressed by Ro31, and the sensitivities of both P-ARs were about 
the same (Figs. 6 and 8). These suggest that the TNF-a increased both P-ARs via the 
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PKC pathway. The issue whether different PKC isoforms play differential roles in the 
induction of P-ARs was not examined in this study. 
As mentioned before, besides PKC, PKA was also interested to be tested. We 
have found that the PKA activator, dbcAMP, could not induce both P-ARs mRNAs 
(Fig. 9). This suggests that the activation of p-AR expression was not mediated 
through PKA, but via PKC. Moreover, Lung (1999) in our laboratory showed that TK 
inhibitors could not attenuate the TNF-a-induced P-AR expression in C6 cells. Thus, 
it is suggested that the elevation of P-ARs was not mediated via a TK pathway. It is 
likely that the the PKC signaling pathway is one of the more important pathways in 
this induction process. 
4.3 Relationship between TNF-a and p-adrenergic mechansim in C6 cells 
Our results showed that P-AR expression was induced by TNF-a (Fig. 10)， 
and Lung (1999) has also found that the TNF-a-induced C6 cell proliferation was 
mediated through (3-adrenergic mechanism, we attempted to see if P-adrenergic 
mechanism regulates endogenous TNF-a and TNF-R2 mRNA expression. 
Results in the present study showed isoproterenol could induce both 
endogenous TNF-a (maximum 10 folds) and TNF-R2 mRNA (maximum 5.6 folds) 
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expression in a dose-dependent manner (Figs. 16 and 17). Furthermore, propranolol 
suppressed the TNF-a-induced endogenous TNF-a and TNF-R2 mRNA in a dose-
dependent manner (Figs. 16 and 17). These suggest that p-adrenergic mechanism 
regulates endogenous TNP-a, and TNF-R2 gene expression in C6 cells. Since there 
are at least 2 p-AR subtypes in the brain (Imura et al., 1999) and C6 cells (Hough & 
Chuang, 1990; Zhong & Minneman, 1993)，we investigated which receptor subtype 
plays a more important role in inducing the expression of TNF-R2 and endogenous 
TNF-a in C6 cells. Our study showed that both pi-agonist, dobutamine, and (32-
agonist, procaterol, could induce endogenous TNF-a mRNA expression in a dose-
dependent manner (Figs. 18 and 23)，and also selectively enhanced the TNF-R2 
mRNA expression in a dose- and time-dependent manner (Figs. 20, 21, 25 and 26). 
This indicated that activation of both (31- and P2-AR could result in the induction of 
endogenous TNF-a and TNF-R2 gene expressions in C6 cells. Supporting this notion 
is our finding that the TKF-a-induced endogenous TNP-a and TNF-R2 mRNA 
expressions were inhibited by selective pl-antagonist, atenolol and j32-antagonist, ICI 
118,551 (Figs. 19, 22, 24 and 27). Thus, this suggested that both pl- and p2-ARs 
could regulate the expression of endogenous TNF-a and TNF-R2 in C6 cells. 
In comparing the results obtained with selective (31- and P2-agonists and -
antagonists (Figs. 20-22, 25-27), we found that P2-agonist was more effective (Fig. 25) 
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in inducing the expression of TNF-R2 expression, while pi-antagonist caused a 
relative large inhibition (>3-fold) of TNF-a-induced TNP-R2 expression (Fig. 22). 
We tentatively concluded that both P-ARs are important in the regulation of TNF-a 
and TNF-R2 expression in C6 cells. This thought is agreement with the report that 
both P-ARs were expressed in C6 cells (Hough & Chuang，1990; Zhong & Minneman^ 
1993), that norepinephrine induced the IL-6 production in astrocytes (Norris & 
Benvensite, 1993) and that isoproterenol increased DL-IO production in mouse 
peritoneal macrophages (Suberville et al., 1996). Moreover, Guirao et al (1997) 
found that catecholamines increased monocyte TNF-R2, but not TNF-Rl expression, 
and inhibited that of TNF-a via p2-adrenergic activation. Moreover, Stevem et al 
(1992) found that preincubation of THP-1 cells with isoproterenol before LPS 
stimulation resulted in increased TNP-a production. Also，Murray et al. (2000) 
reported that isoproterenol significantly increased TNF-a mRNA and protein 
expression in myocardium. However, Nakamura et al. (1999) demonstrated that the 
stimulatory effect of LPS on TNF-a transcription was suppressed by isoproterenol in 
the rat renal resident macrophage cells. This report though contradicts our findings, 
nevertheless supports the notion there interactions exist between TNF-a and P-
adrenergic mechanism. These contradictions maybe due to different cell lines used. 
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4.4 Effects of TNF-a on the expression of a transcriptional factor Nuclear Factor 
Kappa B (NF-KB) in C6 glioma cells 
Following the investigation on the second messenger, it would be natural to 
examine the response of transcription factors, in this study we concentrated on NF-KB, 
in C6 glioma cells. This factor was chosen as it had been reported that TNF-a 
activation resulted in the activation of NF-KB, which may in turn induce some target 
genes, for example, MnSOD and/or calbindin (Sullivan et al.’ 1999). Moreover, NF-
KB has been shown to be activated by some cytokines and neurotrophic factors and in 
response to various cell stressors (Mattson et al., 2000). More related to our study are 
the reports which that showed NF-KB activity was increased rapidly in the cortex in 
traumatic brain injured rats (Yang et al, 1995; Mattson et aL, 2000). The expression 
of the p50 subunit was chosen for this study because after the NF-KB complex was 
activated, its inhibitory subunit，IKB dissociated from the complex, then the p50-p65 
dimer translocates to the nucleus where the p50 subunit bound to the sequence in 
genes responsive to NF-KB (Tan e^ al‘, 1994; Mattson et aL, 2000). 
Present study showed that the expression of NF-KB/p50 mRNA in C6 cells 
was much enhanced by the treatment of TNF-a (Fig. 28), though it was already found 
in untreated C6 cells. This is in good agreement with a recent study that NF-KB is 
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expressed in C6 glioma cells (Lim et al, 2000). Moreover, as the NF-KB activity was 
increased after brain injury (Yang et al., 1995; Mattson et al, 2000), thus, it is 
possible that NF-KB is induced by the elevated TNF-a after brain injury (Fan et a!., 
1996). This induction could in turn induce other target genes, for example, the 
antioxidant enzyme MnSOD, the calcium-binding protein calbindin D28k^ and 
members of the inhibitor of apoptosis family of proteins (Mattson et al., 2000) in 
order to enhance the proliferative effect of TNF-a. Based on our study, it is likely 
these effects are mediated through TNF-R2 and P-AR induction as they were 
selectively increased by TNF-a (Figs. 4 and 10). 
As p-ARs could regulate astrogliosis and glial scar formation following 
neuronal injury (Griffith & Sutin，1996), so, we also investigated if the TNF-a-
induced NF-KB/p50 mRNA expression was mediated via P-adrenergic mechanism. 
This factor is related astrocyte proliferation (Kirillova et al, 1999; Sullivan et al., 
1999; Mattson et al., 2000). In our study, we found that the NF-KB/p50 mRNA was 
enhanced with the treatment of isoproterenol in a dose-dependent manner (Fig. 29), 
while propranolol suppressed the TNF-a-induced NF-KB/p50 mRNA expression in 
C6 cells (Fig. 29). As a result, it is suggested that the TNF-a-induced NF-KB 
expression was mediated through an p-adrenergic system. As the stimulation with 
TNF-a (>7 folds, after 2-4 hours exposure) (Fig. 28) was greater than that with 
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isoproterenol (Fig. 29)，an alternative pathway unrelated by p-adrenergic mechanism 
cannot be excluded. 
Though TNF-a could induce NF-KB mRNA in C6 cells, the second messenger 
involved was still unknown. We demonstrated that PMA could enhance ( � 3 folds) the 
mRNA expression of NF-KB (Fig. 30). The decrease in NF-KB mRNA level in the 
treatment of more concentrated PMA maybe because of a down-regulation effect. 
This indicated that the activation of PKC could induce NF-KB mRNA expression. 
Furthermore, TNF-a-induced NF-KB mRNA expression was inhibited by Ro31 (Fig. 
31), while there was no significant changes in NF-KB mRNA expression when treated 
with Ro31 alone (Fig. 3 lb). So, this suggested that PKC might be the mediator in the 
TNF-a-induced NP-KB expression in C6 cells. Thus, it is likely that the TNP-a-
induced NF-KB mRNA expression maybe mediated via a PKC and P-adrenergic 
mechanism, but not a PKA pathway. 
4.5 Effects of TNF-a on the expression of manganese superoxide dismutase 
rMnSOD^ in C6 glioma cells 
Evidence is mounting that the pivotal step in cell death is mitochondrial 
oxidative stress and/or dysfunction, with recent findings that apoptotic stimuli cause 
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increased accumulation of mitochondrial reactive oxygen species (Sullivan et al., 
1999). These studies also indicate that a reduction in antioxidant production would act 
to increase the susceptibility of neurons to insult. Superoxide accumulation is 
prevented by its conversion to hydrogen peroxide, a process catalyzed by the 
superoxide dismutases Cu/ZnSOD and MnSOD; Cu/ZnSOD is a cytoplasmic enzyme, 
whereas MnSOD is localized in mitochondria (Weisiger & Fridovich^ 1973). Wong et 
al (1989) have shown that treatment of cells from a kidney line with TNF-a induces 
the expression of mRNA for MnSOD but not for other antioxidant enzymes, such as 
Cu-ZnSOD, catalase, glutathione peroxidase and glutathione transferase. Interestingly, 
by using specific agonists and blocking antibodies to either TNF-Rl or -R2, Smith et 
al. (1994) have shown that TNF-a-mediated induction of MnSOD in human 
melanoma cells is via TNF-Rl, but not via TNF-R2. As C6 glioma cells express both 
TNF-Rs, and TNF-a in C6 cells has a proliferative effect rather than cytotoxic effect, 
we were interested if TNP-a can induce MnSOD in C6 cells that in turn reduces 
N 
apoptosis and possibly exerts its proliferative effect. 
Our data suggest that TNP-a could enhance the mRNA level of MnSOD, but 
not of Cu-ZnSOD, in C6 cells (Fig. 32). This shows the induction of MnSOD was 
specific，and this is also in agreement with the report that treatment with TNP-a can 
induce MnSOD, but not Cu-ZnSOD, in kidney cells (Wong et al., 1989). The TNP-R 
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subtype responsible for the MnSOD in C6 cells was not studied in this study. 
Although TNF-R2 was selectively induced (Figs. 4 and 8), it is still unclear if this 
induction does not involve TNF-Rl. This is of particular importance in view of Smith 
et al. (1994) reported that TNF-Rl mediated the induction of MnSOD in human 
melanoma cells. 
We have also found that P-adrenergic mechanism was also involved in the 
TNF-a-induced MnSOD expression, as isoproterenol greatly enhanced MnSOD 
expression, while propranolol suppressed the induction by TNF-a (Fig. 33). Thus, the 
induction of this enzyme in C6 cells is mediated through an P-adrenergic mechanism. 
In our study whether PKC was the signaling pathway on MnSOD expression in C6 
cells was examined, we found that PMA increased MnSOD mRNA expression (Fig. 
34) and that the TNF-a-induced MnSOD expression was prevented by Ro31，a potent 
PKC inhibitor (Fig. 35). This is in good agreement with a previous study with A549 
cells (a human lung adrenocarcinoma cell line) showing that PMA stimulated 
MnSOD expression (Das et al., 1998). Moreover, Kobayashi et al (1997) showed that 
PKC inhibitors augmented TNF-a-induced apoptosis in human embryomic lung 
fibroblast cells by inhibiting cellular resistance factors, including MnSOD. 
From the above discussion, it is clear that TNF-a induced MnSOD expression, 
likely via an p-adrenergic mechanism and a PKC pathway, in C6 cells. Since TNP-a 
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can induce both pi- and P2-AR expression in C6 cells (Fig. 10) and that both p-ARs 
are found in these cells (Hough & Chuang, 1990; Zhong & Minneman^ 1993)，it is 
likely both receptor subtypes are involved. The PKC isoform involved in this 
induction has not been investigated in the present study. In view of recent findings in 
our laboratory showing that PKC< was rapidly induced upon the addition of TNF-a 
(Lung, 1999) and that PKC-y expression was increased by A23187, a Ca^^ ionophore, 
it is tentatively suggested these two PKC isoforms may play more important role(s) in 
this induction process, 
4.6 Possible sources of g-agonists 
In the present study, we found that TNF-a induced pi- and p2-AR expression 
and that both receptor subtypes played a regulatory role in TNF-a, TNF-RL, NF-KB 
and MnSOD expression. One of the interesting points worthy of discussion is the 
source(s) of the j3-agonist in our study. Since serum was one of the ingredients added 
in our cultures (Section 2.1.2.1 and 2.1.2.2)，and that norepinephrine (NE) and 
epinephrine (E) are known to be present in the serum (Dibner and Insel, 1981), it is 
likely that one of the possible sources of |3-agonist is from the serum used. As the 
concentrations of NE and E in the serum are likely to be low, the possibility of other 
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p-agonist-like substances cannot be excluded. 
4.7 CoilclusiQns 
According to our findings, a hypothesis of the relationship among the TNF-a-
mediated events in C6 glioma cells can be proposed as depicted in Fig. 47. Previously, 
we found that C6 cell proliferation was stimulated by TNF-a (Liu, 1996; Lung, 1999). 
As To (1999) found that anti-TNF-R2 antibody, but not anti-TNF-Rl antibody, 
blocked the proliferation effect of TNF-a, thus, the proliferative effect of TNF-a is 
likely through the selective activation of TNF-R2 in C6 cells. After the binding of 
TNF-a to TNF-R2, the expression of (31- and (32-AR were induced, and this is via the 
PKC signaling pathway. Among the PKC isoenzymes, we believe PKC-(^ and -y may 
play more important role(s) in this process. The reasons are: (1) was rapidly 
elevated upon the addition of TKF-a (Lung, 1999); and (2) TNF-a increased the 
intracellular free Ca'^ level within seconds as demonstrated by confocal microscopy, 
following the addition of TNF-a, and that A23187, a Ca〕. ionophore, greatly and 
rapidly induced the expression PKC-丫（To, 1999). However, the exact mechanism 
would require further results with selective PKC isoform inhibitors (Das et aL，1998). 
Activation of both P-ARs are important in the up-regulation of TNF-a and TNF-R2 
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expression in C6 cells. And this suggests that activation of p-adrenergic mechanism 
can additionally induced the proliferation of C6 cells and emphasizes the importance 
of the p-adrenergic mechanism in this process. The activation of p-adrenergic 
mechansim in turn induces the transcription factor, NP-KB, and NF-KB may play an 
important role in C6 cell proliferation. This is supported by the report of Kirillova et 
al. (1999), in which they found that NF-KB is an essential component of the TKF-a 
proliferation pathway in LE6 cells (a rat liver epithelial cell line), and that blockage of 
NF-KB inhibits TNF-a-induced proliferation. Subsequently, the induction of this 
transcription factor then induced one of its target genes, MnSOD, which can remove 
reactive oxygen species produced after brain injury and prevent apoptosis. Although it 
is uncertain whether induction of MnSOD would induce C6 cell proliferation, its 
induction is closely related to antiapoptosis has been clearly demonstrated (Kirillova 
et al, 1999; Mattson et al.，2000). 
One of the major aims of this study is to characterize the signaling pathway 
mediating the TNF-a-induced astrocyte proliferation, using C6 cells as a model. As 
astrocyte proliferation may lead to astrogliosis which has been proposed to block 
axon regeneration and in turn affects the outcome of brain injury (Fawcett & Geller， 
1998), thus a thorough understanding of the signaling pathway mediating the 
proliferation effect of TNF-a and other cytokines should proved to be beneficial to 
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the outcome and treatment of brain injury. 
TNP-a has been shown to increase BBB permeability, damage to myelin and 
oligodendrocytes as well as astrocytic proliferation, a process which may lead to 
astrogliosis and glial scar formation following brain injury (Barone et al., 1997). 
TNF-a has been found to be greatly elevated at the site of injury (Fan et al.’ 1996; 
Kamei et al, 2000) and that agents, such as TNF-a binding protein, HU-211 or 
soluble TNF-a receptor, which lower TNF-a are very effective in improving the 
outcome of brain injury (Shohami et aL, 1997). Our study with C6 cells demonstrated 
that TNF-a selectively induced the induction of TNF-R2 expression, and this is 
mainly mediated by PKC. These findings suggest the important roles of these two 
entities in brain injury. 
TNF-R2 was found to responsible for the proliferative action of TNF-a in C6 
cells (To, 1999). Interestingly, the protective effect of TNF-R2 to injured cells has 
been demonstrated using antisense oligonucleotides for TNF-R2 (Shen et al., 1997) 
and genetically-deficient TNF-R2 mice (Lucas et aL, 1997). The finding that PKC is a 
messenger mediating the action of TNF-a in C6 cells is in line with observations in 
other cell types, such as erythroblastoid leukemia K562 cells (Zhang et aL, 1994). 
PKC has been shown to be a very common second messenger (Padma-pemma et a/., 
1996; Zablocka et aL, 1998). Recent studies have shown that only PKC-y, one of the 
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PKC isoforais that is calcium-dependent, could be particularly sensitive to ischemic 
insult in gerbil hippocampus (Zablocka et al., 1998)，and this isoform has been found 
to be induced after exposure to TNF-a in C6 cells (Lung, 1999) and to calcium 
ionophore, A23187 (To, 1999). These suggest PKC is an important step in controlling 
C6 cells as well as astrocytes proliferation and PKC-y appears to be more closely 
associated to this process. 
One of the important observations in the present study is the induction of p-
ARs by TNF-a. This is because p-adrenergic blockade had been shown to reduce 
astrogliosis and improve the outcome of nerve injury (Sutin & Griffith^ 1993; 
Hodges-Savola et al.，1996). We found that both (31- and P2-agonists can induce 
TNF-a and TNF-R2 expressions in C6 cells, while their antagonists can suppress their 
TNF-a-induced expressions. The latter observation would provide a reasonable 
explanation for the beneficial effect of P-antagonists on brain injury (Sutin & Griffith， 
1993; Hodges-Savola et al, 1996) and emphasizes this is one of the important 
controlling points in treating brain injury. 
Our study provides an explanation for the two seeming unrelated observations: 
elevation of TNF-a observed in brain injury and (3-AR blockade improve the outcome 
of brain injury. More importantly, our results suggest that combined treatment with 
anti-TNF-a drugs/agents and P-AR antagonists is a more effective mean than either 
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compound alone for brain injury. The observation that TNF-a-induced NF-KB 
expression is interesting as its activity was found to be increased after brain injury 
(Yang et al., 1995; Mattson et a/., 2000), and that this factor has been shown to be 
closely related to cell proliferation (Tan et al., 1994; Yang et a!‘, 1995; Mattson et cd., 
2000). Moreover, NF-KB has been shown to induce a number of genes, such as 
MnSOD, calcium binding protein calbindin D28k (Mattson et al., 1995). 
In agreement with studies with kidney cells (Wong et aL, 1989)，TNF-a was 
found to induce MnSOD in C6 cells. The induction of MnSOD in cells is known to 
reduce apoptosis (Wong et al., 1989; Kobayashi et al, 1997; Das et a!‘, 1998). TNF-a 
in C6 cells does not induce apoptosis, and this maybe related to the induction of 
MnSOD, and its induction of TNF-R2, a receptor subtype reported to be responsible 
for proliferation (Tartaglia et a!., 1993). 
I f the present study has any direct bearings on the treatment of brain injury, 
our results suggest that blockade TNF-a action, inhibition of TNF-R2 and P-AR 
expression as well as their activities, PKC activity, as well as the reduction of ISHF-KB 
expression are strategic points worthy of serious consideration. 
.iV 
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Restriction enzyme digestion of the PCR products 
The PCR bands with predicted sizes shown in this thesis were further checked by 
restriction enzyme (RE) digestion, except those already done by my collaborators 
(Huang et cd., 1998; Lung, 1999; To, 1999). They were found to contain the predicted 
restriction sites for all the amplified cDNA products. The RE digestions produced 
pieces with predicted.sizes as shown Figs. 37 and 38, confirming that these products 
did result from amplification of the corresponding transcripts. Note that incomplete 
digestion can be observed in Cu-ZnSOD (Fig. 37). 
Cu-ZnSOD 
M BstNI PstI 
241 bp bp 
H H ^ ^h ^ ^ H ^ ^ ^ S I I - I T I bp 
141 bp - i m i ^ ^ ^ m 
— 
B H 
Fig. 37 Restriction enzyme digestion of amplified Cu-ZnSOD cDNA and found to contain the 
predicted Est NI and Pst I restriction sites. DNA fragments with predicted restriction 








Fig. 38 Restriction enzyme digestion of amplified MnSOD cDNA and found to 
contain the predicted Pvu II and Stu I restriction sites. DNA fragments with 
predicted restriction sizes were shown. 
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